1. Metabolic Enzyme/Protease
    Autophagy
  2. Proteasome
    Autophagy

Bortezomib (Synonyms: PS-341)

Cat. No.: HY-10227 Purity: 99.72%
Data Sheet SDS Handling Instructions

Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM.

For research use only. We do not sell to patients.
Bortezomib Chemical Structure

Bortezomib Chemical Structure

CAS No. : 179324-69-7

Size Price Stock Quantity
10 mM * 1 mL in DMSO $55 In-stock
5 mg $50 In-stock
10 mg $60 In-stock
50 mg $90 In-stock
100 mg $150 In-stock
200 mg $240 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM.

IC50 & Target

Ki: 0.6 nM (20S proteasome)[1]

In Vitro

Bortezomib (PS-341) effects proteins that control cell cycle progression. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. The Bortezomib doses at which 50% of PC-3 cells are killed at 24 and 48 h are determined to be 100 and 20 nM, respectively[1]. Bortezomib is a highly selective, reversible inhibitor of the 26S proteasome. Inhibition of the proteasome by Bortezomib results in activation of JNK, stabilization of p53, Bid, Bax, p21, p27, caveolin-1, and IκBα, resulting in inhibition of NF-κB[2]. The IC50 of Bortezomib is found to be 2.46 nM for 26S proteasome in the B16F10 cells[3].

In Vivo

Mice bearing PC-3 tumors are treated with Bortezomib (i.v., 0.3 or 1.0 mg/kg). Bortezomib (1.0 mg/kg) results in a significant decrease in tumor growth ~60%. Bortezomib (0.3 mg/kg) produces a 16% decrease in tumor volume but did not reach significance[1]. Bortezomib (0.2 mg/kg) significantly decreases the withdrawal threshold on days 11 and 15 and increases the number of withdrawal responses on days 11 and 15 compared with the vehicle group in the von Frey and acetone tests[4].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00408928 Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University Graft-versus-Host Disease November 2005 Phase 2
NCT01929980 Children's Hospital Medical Center, Cincinnati Allogeneic Stem Cell Transplantation|Refractory Autoimmune Cytopenia(s) July 2012 Phase 2
NCT00644696 University of Michigan Cancer Center|Millennium Pharmaceuticals, Inc. Neuroblastoma April 2008 Phase 1
NCT01163786 Northwestern University|Robert H. Lurie Cancer Center Bronchiolitis Obliterans July 2010 Phase 2
NCT01090921 Boston VA Research Institute, Inc.|Millennium Pharmaceuticals, Inc. Multiple Myeloma May 2007 Phase 2
NCT01801436 Johnson & Johnson Taiwan Ltd Multiple Myeloma December 2006 Phase 3
NCT00657553 University of Arkansas Multiple Myeloma February 2008 Phase 3
NCT01672229 University of California, Davis|Millennium Pharmaceuticals, Inc. Graft Versus Host Disease July 2012 Phase 1
NCT03013114 Shandong University Immune Thrombocytopenia January 2017 Phase 2
NCT02268890 Johnson & Johnson Taiwan Ltd Multiple Myeloma December 2014 Phase 4
NCT01158105 Baylor Research Institute|Millennium Pharmaceuticals, Inc. Chronic Graft-versus-host Disease June 2010 Phase 2
NCT01328236 Clinical Service, China|Harbin Hematology and Oncology Institute|Shanghai Changzheng Hospital|Chinese PLA General Hospital|307 Hospital of PLA|Wuhan Union Hospital, China|Beijing Chao Yang Hospital|Henan Provincial Hospital|Peking University Third Hospital Plasma Cell Leukemia|Multiple Myeloma September 2010 Phase 2
NCT01517724 University College, London Multiple Myeloma December 2009 Phase 2
NCT00153933 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|H. Lee Moffitt Cancer Center and Research Institute Refractory Multiple Myeloma|Relapsed Multiple Myeloma|Multiple Myeloma August 2004 Phase 1
NCT02102594 Charite University, Berlin, Germany|Prof. Dr. med. Falk Hiepe (Charité, Internal Medicine / Rheumathology)|NeuroCure Clinical Research Center - Charité (Berlin) Myasthenia Gravis|Systemic Lupus Erythematosus|Rheumatoid Arthritis October 2014 Phase 2
NCT03103555 Mahidol University|Ministry of Health, Thailand Adult-onset Immunodeficiency February 27, 2017 Phase 2
NCT00093704 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Lymphoma|Lymphoproliferative Disorder March 2005 Phase 1
NCT00815919 Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc. Chronic Graft Versus Host Disease December 2008 Phase 2
NCT00789256 Dartmouth-Hitchcock Medical Center|Millennium Pharmaceuticals, Inc. Acute Myelogenous Leukemia|Myelodysplastic Syndromes September 2004
NCT00153920 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Brigham and Women's Hospital|Roswell Park Cancer Institute|Emory University|Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc. Multiple Myeloma December 2003 Phase 2
NCT01695330 Oncotherapeutics|Millennium Pharmaceuticals, Inc. Multiple Myeloma May 2012 Phase 2
NCT01965977 Samsung Medical Center|Janssen, LP Diffuse Large B Cell Lymphoma July 2013 Phase 2
NCT02254551 SCRI Development Innovations, LLC|Novartis Multiple Myeloma January 2015 Phase 2
NCT02308280 Maisonneuve-Rosemont Hospital Multiple Myeloma|High-Risk Cancer November 2014 Phase 2
NCT00622674 Masonic Cancer Center, University of Minnesota Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Pancreatic Cancer|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific November 2005 Phase 1
NCT01902862 Janssen-Cilag G.m.b.H Lymphoma, Follicular February 2006 Phase 2
NCT00620295 Masonic Cancer Center, University of Minnesota Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Sarcoma March 2007 Phase 1
NCT00581360 University of Pittsburgh|Millennium Pharmaceuticals, Inc. Adenoid Cystic Carcinoma November 2007 Phase 2
NCT01171092 University of Kansas Medical Center|Millennium Pharmaceuticals, Inc. Malignant Lymphoma, Stem Cell Type|Autologous Transplant September 2010 Early Phase 1
NCT00288028 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm July 2005 Phase 1
NCT00642395 University Hospital, Toulouse|Intergroupe Francophone du Myelome Multiple Myeloma July 2007 Phase 2
NCT00714246 Milton S. Hershey Medical Center|Sanofi Non Small Cell Lung Cancer October 2008 Phase 1|Phase 2
NCT00671112 Brian Hill, MD, PhD|National Cancer Institute (NCI)|The Leukemia and Lymphoma Society|Case Comprehensive Cancer Center 714leukemia|Lymphoma June 2008 Phase 1
NCT03129828 Prof. Dr. Clemens Schmitt|Charite University, Berlin, Germany|Janssen-Cilag Ltd. Diffuse Large B Cell Lymphoma March 17, 2017 Phase 1|Phase 2
NCT00784823 Hackensack University Medical Center Multiple Myeloma January 2007 Phase 1|Phase 2
NCT01842074 Assistance Publique - Hôpitaux de Paris Patients Awaiting a Living Kidney Donation March 2013 Phase 4
NCT01736943 University of California, Davis|Millennium Pharmaceuticals, Inc. Acute Myelogenous Leukemia December 2012 Phase 2
NCT00006773 National Cancer Institute (NCI) Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor May 2001 Phase 1
NCT02893111 Tianjin Medical University General Hospital Neuromyelitis Optica Spectrum Disorder December 2015 Phase 2
NCT01485835 Emory University|Multiple Myeloma Research Consortium|Synta Pharmaceuticals Corp. Multiple Myeloma January 2012 Phase 1
NCT01453088 Hackensack University Medical Center Multiple Myeloma June 2010 Phase 2
NCT00417911 Nordic Myeloma Study Group|Janssen-Cilag Ltd. Multiple Myeloma December 2005 Phase 3
NCT01812096 The First Affiliated Hospital of Soochow University Multiple Myeloma Proved by Laboratory Tests May 2014 Phase 1|Phase 2
NCT01273844 Zhi-Hong Liu, M.D.|Soochow University|Nanjing Medical University|Nanjing University School of Medicine Amyloidosis March 1, 2011
NCT00765102 Celgene Corporation Multiple Myeloma September 2008 Phase 2
NCT02220608 Washington University School of Medicine|Millennium Pharmaceuticals, Inc. Multiple Myeloma February 20, 2015 Phase 1
NCT00903968 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Genzyme, a Sanofi Company|Millennium Pharmaceuticals, Inc. Multiple Myeloma May 2009 Phase 1|Phase 2
NCT01534260 Hamid Sayar|Millennium Pharmaceuticals, Inc.|Bayer|Merck Sharp & Dohme Corp.|Indiana University Acute Myeloid Leukemia February 10, 2012 Phase 1|Phase 2
NCT01497626 Georgetown University|GlaxoSmithKline|Millennium Pharmaceuticals, Inc. Advanced Solid Tumors September 2011 Phase 1
NCT01058239 Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Millennium Pharmaceuticals, Inc. Post-transplant Lymphoproliferative Disease|Solid Organ Transplant|Stem Cell Transplant (Bone Marrow Transplant)|Epstein Barr Virus Infections November 2011 Phase 2
NCT00040768 National Cancer Institute (NCI) Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer April 2002 Phase 2
NCT00372905 Northwestern University|Robert H. Lurie Cancer Center Lymphoma August 2006 Phase 1|Phase 2
NCT00983346 University of Utah|Millennium Pharmaceuticals, Inc. Cancer|Myeloma|Multiple Myeloma October 2009 Phase 2
NCT00923247 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Medullary Thyroid Carcinoma February 19, 2009 Phase 1|Phase 2
NCT00104871 National Cancer Institute (NCI) Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer December 2004 Phase 2
NCT01696474 Gruppo Italiano Malattie EMatologiche dell'Adulto Refractory Cold Agglutinin Disease December 2012 Phase 2
NCT00580320 Virginia Commonwealth University Melanoma|Soft Tissue Sarcoma|Parathyroid Carcinoma|Small Cell Carcinoma of the Lung|Carcinoid Tumors September 2004 Phase 1
NCT00059631 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.|National Cancer Institute (NCI) Prostate Cancer March 2003 Phase 1
NCT02613598 University of Michigan Cancer Center Hodgkin's Lymphoma|Lymphoma, Non-Hodgkin January 2016 Phase 1
NCT02370693 Northwestern University|National Heart, Lung, and Blood Institute (NHLBI) Interstitial Lung Disease|ILD|Systemic Sclerosis|Scleroderma March 2016 Phase 2
NCT00901147 Singapore General Hospital Peripheral T-cell Lymphoma (Not Otherwise Specified)|Angioimmunoblastic T-cell Lymphoma|Extranodal NK/T-cell Lymphoma Nasal Type|Enteropathy- Type T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)|Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant November 2009 Phase 2
NCT00422799 Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc. Waldenstrom's Macroglobulinemia September 2006 Phase 2
NCT00431769 Janssen-Cilag International NV Multiple Myeloma June 2006 Phase 2
NCT00373906 Medical University of Vienna MALT Lymphoma Phase 2
NCT00777738 Assistance Publique - Hôpitaux de Paris Waldenstrom Macroglobulinemia October 2008 Phase 2
NCT00424840 University of Massachusetts, Worcester|Millennium Pharmaceuticals, Inc.|Genentech, Inc. Lung Cancer June 2006 Phase 1|Phase 2
NCT01504477 Georgetown University|Millennium Pharmaceuticals, Inc. Colorectal Cancer December 2011 Phase 1|Phase 2
NCT00508209 Nordic Myeloma Study Group|Janssen-Cilag Ltd. Multiple Myeloma July 2007 Phase 2
NCT01891968 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Leukemia August 7, 2013 Phase 2
NCT01930253 Children's Hospital Medical Center, Cincinnati Refractory Autoimmune Cytopenia(s) July 2012 Phase 1
NCT02356458 Swiss Group for Clinical Cancer Research Mantle Cell Lymphoma August 2015 Phase 1|Phase 2
NCT01524445 Janssen Pharmaceutica N.V., Belgium Hematological Cancer|Multiple Myeloma March 2011 Phase 4
NCT01046006 Meletios A. Dimopoulos|European Myeloma Network|University of Athens Waldenstrom's Macroglobulinemia March 2007 Phase 2
NCT00504634 M.D. Anderson Cancer Center Multiple Myeloma January 2004 Phase 2
NCT00103272 National Cancer Institute (NCI) Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia Wit April 2005 Phase 1
NCT00538187 National Cancer Institute (NCI) Adult Non-Hodgkin Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma December 2007 Phase 1
NCT00516100 Aptium Oncology Research Network|Millennium Pharmaceuticals, Inc. Non-small Cell Lung Cancer January 2006 Phase 1|Phase 2
NCT01397591 OHSU Knight Cancer Institute|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.|GlaxoSmithKline Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma October 2011 Phase 2
NCT01833143 Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc. Non-Small Cell Lung Cancer April 2013 Phase 2
NCT00428545 M.D. Anderson Cancer Center Advanced Malignancy|Lymphoma|Myeloma|Solid Tumors January 2007 Phase 1
NCT01241708 Hackensack University Medical Center Multiple Myeloma|Auto Stem Cell Transplant April 2010 Phase 3
NCT00990652 Northwestern University|Millennium Pharmaceuticals, Inc. Brain and Central Nervous System Tumors May 2009 Phase 2
NCT00072150 National Cancer Institute (NCI) Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Stage III Bladder Cancer|Stage III Urethral Cancer|Stage IV Bladder Cancer|Stage IV Urethral Cancer|Transitional Cell Carcinoma of the Bladder|Ureter Cancer October 2003 Phase 2
NCT00773838 Merck Sharp & Dohme Corp. Relapsed or Refractory Multiple Myeloma December 2008 Phase 2
NCT01183949 Astex Pharmaceuticals|Multiple Myeloma Research Consortium Multiple Myeloma November 2010 Phase 1|Phase 2
NCT00718640 Janssen-Ortho Inc., Canada Multiple Myeloma October 2007 Phase 2
NCT02351427 Asan Medical Center Kidney Transplantation February 2015 Phase 3
NCT02336386 Beijing Chao Yang Hospital|Peking University People's Hospital Extramedullary Plasmacytoma December 2014 Phase 3
NCT00410423 Thomas Jefferson University|Millennium Pharmaceuticals, Inc. Relapsed Acute Leukemia|Refractory Acute Leukemia January 2006 Phase 1|Phase 2
NCT00920855 Cephalon|Teva Pharmaceutical Industries Multiple Myeloma June 2009 Phase 1|Phase 2
NCT00315757 Human Genome Sciences Inc. Multiple Myeloma May 2006 Phase 2
NCT00483262 Dana-Farber Cancer Institute|Wyeth is now a wholly owned subsidiary of Pfizer|Millennium Pharmaceuticals, Inc. Multiple Myeloma May 2007 Phase 1|Phase 2
NCT00570180 University Health Network, Toronto|Princess Margaret Hospital, Canada|Ortho Biotech, Inc. Multiple Myeloma November 2007 Phase 2
NCT01103778 The Rogosin Institute|Weill Medical College of Cornell University Chronic Kidney Disease|IgA Nephropathy July 2010 Phase 4
NCT00479128 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Solid Tumor|Urethral Cancer September 2006 Phase 1
NCT02201576 Assistance Publique - Hôpitaux de Paris|Fondation Centaure Chronic Antibody-mediated Transplant Rejection February 2015 Phase 2
NCT00773747 Merck Sharp & Dohme Corp. Multiple Myeloma December 2008 Phase 3
NCT02467010 University Medical Center Groningen Multiple Myeloma September 2008 Phase 2
NCT00348985 National Cancer Institute (NCI) Adult Grade III Lymphomatoid Granulomatosis|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cel March 2006 Phase 1
NCT00305734 National Cancer Institute (NCI) Recurrent Nasopharyngeal Cancer|Stage IV Nasopharyngeal Cancer August 2006 Phase 2
NCT01023308 Novartis Pharmaceuticals|Novartis Multiple Myeloma December 2009 Phase 3
NCT00287872 Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI) Multiple Myeloma September 2004 Phase 2
NCT00793650 Emory University|Millennium Pharmaceuticals, Inc. Cancer|Multiple Myeloma May 2005 Phase 1|Phase 2
NCT01005628 Janssen Korea, Ltd., Korea Multiple Myeloma June 2006 Phase 4
NCT00290706 Northwestern University|Eli Lilly and Company|Millennium Pharmaceuticals, Inc. Lymphoma September 2005 Phase 1|Phase 2
NCT00722722 Mayo Clinic|Millennium Pharmaceuticals, Inc. Kidney Transplantation June 2008 Phase 2
NCT00142129 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Millennium Pharmaceuticals, Inc. Waldenstrom's Macroglobulinemia|Lymphoplasmacytic Lymphoma December 2003 Phase 2
NCT01226849 Singapore General Hospital|Janssen-Cilag Ltd. Diffuse Large B-Cell Lymphoma November 2010 Phase 1
NCT00492050 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Waldenstrom's Macroglobulinemia August 2006 Phase 2
NCT00083226 National Cancer Institute (NCI) Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer March 2004 Phase 2
NCT01030302 Janssen Korea, Ltd., Korea Multiple Myeloma November 2008 Phase 4
NCT00972712 Emory University|Millennium Pharmaceuticals, Inc.|Ortho Biotech, Inc. Multiple Myeloma December 2006 Phase 1
NCT00054483 National Cancer Institute (NCI) Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Ly January 2003 Phase 1
NCT00369707 Northwestern University|Robert H. Lurie Cancer Center Non-Hodgkin's Lymphoma August 2006 Phase 2
NCT01873157 Medical University of Vienna|Medical University Innsbruck Late Rejection of Renal Transplant|Antibody-mediated Rejection December 2013 Phase 2
NCT00516191 University of California, San Francisco Multiple Myeloma October 2004 Phase 1|Phase 2
NCT00250926 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Millennium Pharmaceuticals, Inc. Waldenstrom's Macroglobulinemia October 2005 Phase 2
NCT00352742 Attenuon Multiple Myeloma June 2006 Phase 1|Phase 2
NCT00985907 University of California, San Francisco Multiple Myeloma|Patient Participation June 2004 Phase 1|Phase 2
NCT00118144 National Cancer Institute (NCI) Adenocarcinoma of the Lung|Bronchoalveolar Cell Lung Cancer|Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer June 2005 Phase 2
NCT00633594 SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc.|Celgene Mantle Cell Lymphoma June 2008 Phase 1|Phase 2
NCT00059618 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer April 2003 Phase 1
NCT00833560 Janssen-Cilag G.m.b.H Multiple Myeloma March 2006 Phase 2
NCT02976272 University Hospital, Clermont-Ferrand|Laboratoires Takeda Multiple Myeloma|Bortezomib Regimen|Adult September 2016
NCT03016988 Tingbo Liu|Union hospital of Fujian Medical University|Fujian Medical University Mantle Cell Lymphoma January 2017 Phase 2
NCT00891033 University of Arkansas|Novartis Multiple Myeloma April 2009 Phase 1
NCT02497378 Janssen Pharmaceutical K.K. Multiple Myeloma July 10, 2015 Phase 1
NCT00376961 Southwest Oncology Group|National Cancer Institute (NCI) Lymphoma August 2006 Phase 2
NCT01315873 New York University School of Medicine|Cephalon Multiple Myeloma September 2011 Phase 2
NCT00963274 Virginia Commonwealth University|National Cancer Institute (NCI) Leukemia|Lymphoma April 26, 2010 Phase 1
NCT02811978 Janssen Research & Development, LLC Multiple Myeloma September 27, 2016 Phase 3
NCT01495351 Alberta Health Services|Tom Baker Cancer Centre|Abbott|AHS Cancer Control Alberta Multiple Myeloma January 2012 Phase 1
NCT01168804 Austrian Forum Against Cancer Multiple Myeloma June 2010 Phase 2
NCT01111188 Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.|Pfizer Mantle Cell Lymphoma June 2010 Phase 1
NCT01164709 Swiss Group for Clinical Cancer Research Leukemia|Lymphoma|Mature T-cell and Nk-cell Neoplasms|Multiple Myeloma and Plasma Cell Neoplasm July 2010 Phase 1
NCT02211755 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neoplasms|Myelodysplastic Syndromes July 30, 2014 Phase 1
NCT00752518 Janssen Pharmaceutical K.K. Refractory|Multiple Myeloma|Relapse May 2004 Phase 1|Phase 2
NCT00425503 Baylor College of Medicine|Millennium Pharmaceuticals, Inc. Prostate Neoplasms December 2001 Phase 2
NCT02139397 Giselle Sholler|Beat NB Cancer Foundation|Because of Ezra|Spectrum Health Hospitals Neuroblastoma Recurrent May 2014 Phase 1|Phase 2
NCT00798720 University of Wisconsin, Madison|Millennium Pharmaceuticals, Inc.|Merck Sharp & Dohme Corp. Carcinoma, Non Small Cell Lung December 2008 Phase 2
NCT01462773 Ohio State University Comprehensive Cancer Center Melanoma January 2006 Phase 1
NCT00536575 SCRI Development Innovations, LLC|Bayer Multiple Myeloma November 2007 Phase 1|Phase 2
NCT00426855 Peter Moosmann|Kantonsspital Aarau Lymphoma, Non-Hodgkin January 2007 Phase 1|Phase 2
NCT02188537 Swiss Group for Clinical Cancer Research Myeloma December 2014 Phase 2
NCT00310024 National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma November 2005 Phase 1
NCT00810576 M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp. Lymphoma January 2009 Phase 2
NCT00075881 National Cancer Institute (NCI) Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma January 2004 Phase 2
NCT02237261 University Hospital Heidelberg|German Cancer Research Center|Janssen-Cilag International NV|Mundipharma Research GmbH & Co KG|inVentiv Health Clinical Multiple Myeloma November 2014 Phase 2
NCT01323920 Dana-Farber Cancer Institute Leukemia|Lymphoma|Myelodysplastic Syndrome May 2011 Phase 2
NCT00093769 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Lymphoma August 2004 Phase 2
NCT00611325 Duke University|Millennium Pharmaceuticals, Inc.|Genentech, Inc. Glioblastoma|Gliosarcoma May 2008 Phase 2
NCT01926899 Indiana University Hematopoetic Stem Cell Transplant August 2013 Phase 1
NCT00077441 National Cancer Institute (NCI) Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer April 2005 Phase 2
NCT01860170 Spectrum Health Hospitals|Millennium Pharmaceuticals, Inc. Hematological Malignancy April 2012 Phase 1|Phase 2
NCT02037256 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Co July 2011
NCT00416208 Janssen-Cilag G.m.b.H Multiple Myeloma October 2006 Phase 3
NCT00608907 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Multiple Myeloma|Non-Hodgkin's Lymphoma September 2007 Phase 1
NCT03110562 Karyopharm Therapeutics Inc Multiple Myeloma June 7, 2017 Phase 3
NCT01680796 University of Florida|Novartis Pharmaceuticals Multiple Myeloma February 2013 Phase 1
NCT01062230 University of Arkansas|Millennium Pharmaceuticals, Inc. Multiple Myeloma January 2010 Phase 2
NCT01465386 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Promyelocytic Leukemia (M3)|Adult Ery November 2011 Phase 2
NCT01119794 Brown University|Rhode Island Hospital|The Miriam Hospital|Memorial Hospital of Rhode Island|Dartmouth-Hitchcock Medical Center Lymphoma, Non-Hodgkins July 2010 Phase 2
NCT01029730 SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc.|Cephalon Lymphoma March 2010 Phase 2
NCT02220049 Gustave Roussy, Cancer Campus, Grand Paris Advanced or Metastatic Solid Tumors December 2010 Phase 1
NCT00937495 National Cancer Institute (NCI) Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma June 2009 Phase 2
NCT02353572 University of Colorado, Denver Plasma Cell Myeloma|Plasmacytosis|Recurrent Plasma Cell Myeloma|Smoldering Plasma Cell Myeloma November 2009 Phase 1|Phase 2
NCT01125293 Dana-Farber Cancer Institute|Novartis|Millennium Pharmaceuticals, Inc. Waldenstrom's Macroglobulinemia March 2010 Phase 1|Phase 2
NCT00580242 Massachusetts General Hospital|Celgene Corporation|Dana-Farber Cancer Institute Myelodysplasia November 2007 Phase 1
NCT00334438 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) Lymphoma July 2006 Phase 1
NCT00401011 Keryx / AOI Pharmaceuticals, Inc. Multiple Myeloma|Multiple Myeloma in Relapse August 2006 Phase 1|Phase 2
NCT00734149 Duke University Multiple Myeloma July 2004 Phase 2
NCT00111813 Merck Sharp & Dohme Corp. Multiple Myeloma September 2005 Phase 1
NCT00777114 Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.|GlaxoSmithKline Non-Hodgkin's Lymphoma October 2008 Phase 1
NCT00895687 M.D. Anderson Cancer Center Advanced Cancer April 2009 Phase 1
NCT01536067 Roswell Park Cancer Institute|National Cancer Institute (NCI)|GlaxoSmithKline Waldenström Macroglobulinemia April 2012 Phase 2
NCT02703779 University of Kansas Medical Center Multiple Myeloma March 2016 Phase 2
NCT01497275 Duke University|Spectrum Pharmaceuticals, Inc Mantle-Cell Lymphoma February 2012 Phase 2
NCT01034553 Mayo Clinic Refractory Multiple Myeloma February 2010 Phase 1|Phase 2
NCT00023712 National Cancer Institute (NCI) Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer July 2004 Phase 2
NCT00720148 Emory University|Millennium Pharmaceuticals, Inc.|Pfizer Solid Tumors February 2008 Phase 1
NCT02902965 Pharmacyclics LLC.|Janssen Research & Development, LLC Multiple Myeloma September 2016 Phase 2
NCT01129180 Pierluigi Porcu|Millennium Pharmaceuticals, Inc.|Celgene Corporation|Ohio State University Comprehensive Cancer Center Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Prolymphocytic Leukemia|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Small Intestine Lymphoma|T-cell Large Granular Lymphocyte Leukemia May 2010 Phase 1
NCT02136134 Janssen Research & Development, LLC Multiple Myeloma August 15, 2014 Phase 3
NCT00560352 Bristol-Myers Squibb Multiple Myeloma February 2008 Phase 1
NCT00276614 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Kidney Cancer April 2006 Phase 2
NCT00093028 University of Arkansas Multiple Myeloma January 2004 Phase 3
NCT01016730 National Cancer Institute (NCI) AIDS-Related Kaposi Sarcoma|HIV Infection|Recurrent Kaposi Sarcoma January 22, 2010 Phase 1
NCT01428492 Novartis Multiple Myeloma December 2011 Phase 1
NCT01255527 Yonsei University Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation October 2010 Phase 1|Phase 2
NCT01734928 Celgene Multiple Myeloma January 7, 2013 Phase 3
NCT00920556 Sirtris, a GSK Company|GlaxoSmithKline Multiple Myeloma March 2009 Phase 2
NCT02840539 Seoul National University Hospital|Consortium for Improving Survival of Lymphoma Mantle Cell Lymphoma October 2016 Phase 2
NCT00770731 M.D. Anderson Cancer Center Advanced Cancer September 2008 Phase 1
NCT03136146 M.D. Anderson Cancer Center Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma September 2017 Phase 2
NCT01322776 Sun Yat-sen University|Fudan University|Zhejiang University|West China Hospital|Ruijin Hospital|Tianjin Medical University Cancer Institute and Hospital|Beijing Cancer Hospital|Jiangsu Cancer Institute & Hospital Mantle Cell Lymphoma Recurrent March 2011 Phase 1|Phase 2
NCT01009840 Otsuka Pharmaceutical Development & Commercialization, Inc. Multiple Myeloma May 2010 Phase 2
NCT01568866 Amgen Multiple Myeloma June 2012 Phase 3
NCT01038388 Emory University|Merck Sharp & Dohme Corp.|Celgene Corporation Multiple Myeloma January 15, 2010 Phase 1
NCT01492881 UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp. Multiple Myeloma April 2012 Phase 2
NCT01497093 Celgene|Multiple Myeloma Research Consortium Multiple Myeloma February 15, 2012 Phase 1
NCT00023764 National Cancer Institute (NCI) Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma June 2001 Phase 2
NCT02658396 Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Phase 1
NCT01286077 Janssen-Cilag International NV Multiple Myeloma September 2009 Phase 2
NCT00664898 Genentech, Inc.|Seattle Genetics, Inc. Multiple Myeloma May 2008 Phase 1
NCT01711528 National Cancer Institute (NCI) Recurrent Plasma Cell Myeloma December 19, 2012 Phase 1
NCT02100657 PharmaMar Multiple Myeloma June 2014 Phase 1
NCT00030368 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific November 2001 Phase 1
NCT00439556 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Lymphoma February 2007 Phase 2
NCT02224729 Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma August 2014 Phase 2
NCT00791011 Amgen Hodgkin's Lymphoma|Low Grade Lymphoma|Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Diffuse Large Cell Lymphoma February 2008 Phase 1
NCT01021592 Janssen Korea, Ltd., Korea Multiple Myeloma March 2007 Phase 4
NCT00310037 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc. Mantle Cell Lymphoma June 2006 Phase 2
NCT01861314 National Cancer Institute (NCI) Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia July 3, 2013 Phase 1
NCT00837174 The Methodist Hospital System Non-Hodgkin Lymphoma June 2010 Phase 2
NCT00005064 National Cancer Institute (NCI) Adult Acute Promyelocytic Leukemia (M3)|Blastic Phase Chronic Myelogenous Leukemia|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia February 2000 Phase 1
NCT00651781 PETHEMA Foundation Acute Myeloid Leukemia April 2008 Phase 1|Phase 2
NCT00479167 Rush University Medical Center|GlaxoSmithKline|Millennium Pharmaceuticals, Inc. Follicular Lymphoma May 2007 Phase 2
NCT02773550 Basque Health Service Multiple Myeloma January 2014 Phase 4
NCT00061932 National Cancer Institute (NCI) Adenocarcinoma of the Gastroesophageal Junction|Diffuse Adenocarcinoma of the Stomach|Intestinal Adenocarcinoma of the Stomach|Mixed Adenocarcinoma of the Stomach|Recurrent Gastric Cancer|Stage IIIB Gastric Cancer|Stage IIIC Gastric Cancer|Stage IV Gastric Cancer April 2003 Phase 2
NCT01530594 King Faisal Specialist Hospital & Research Center Multiple Myeloma January 2009 Phase 3
NCT00182637 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Lymphoma July 2004 Phase 2
NCT02197221 University Hospital, Toulouse|Ministry of Health, France|Janssen, LP Multiple Myeloma January 2015 Phase 3
NCT00416273 Janssen-Cilag G.m.b.H Multiple Myeloma December 2006 Phase 3
NCT00440765 Janssen-Cilag B.V. Multiple Myeloma|Hematological Neoplasms November 2004 Phase 4
NCT01695941 National Cancer Institute (NCI) Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Mantle Cell Lymphoma August 31, 2012 Phase 1
NCT01083602 Novartis Pharmaceuticals|Novartis Relapsed and Bortezomib Refractory Multiple Myeloma|Refractory Multiple Myeloma|Multiple Myeloma in Relapse June 2010 Phase 4
NCT00136591 Lymphoma Study Association|Janssen-Cilag International NV Follicular Lymphoma September 2005 Phase 2
NCT00271804 Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center Myelodysplastic Syndrome June 2005 Phase 1
NCT00818649 Masonic Cancer Center, University of Minnesota|Merck Sharp & Dohme Corp.|Millennium Pharmaceuticals, Inc. Leukemia|Myelodysplastic Syndrome January 2009 Phase 2
NCT00670423 Jennifer E. Schwartz|Millennium Pharmaceuticals, Inc.|Indiana University Graft vs Host Disease|Peripheral Blood Stem Cell Transplantation|Transplantation, Homologous May 2008 Phase 1
NCT02977494 University Hospital Tuebingen Multiple Myeloma December 2016 Phase 2
NCT02797041 IRCCS Centro di Riferimento Oncologico della Basilicata Multiple Myeloma August 2015
NCT01818752 Amgen Multiple Myeloma March 2013 Phase 3
NCT00742625 National Cancer Institute (NCI) Acute Myeloid Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leu September 2008 Phase 1|Phase 2
NCT00439361 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Hodgkin Lymphoma|Lymphoma February 2007 Phase 1
NCT00383474 National Cancer Institute (NCI) Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With August 2006 Phase 1
NCT00477412 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Mantle Cell Lymphoma|Lymphoma April 2007 Phase 1
NCT01440582 M.D. Anderson Cancer Center|Novartis Myeloma February 18, 2013 Phase 1
NCT01026701 Janssen Korea, Ltd., Korea Multiple Myeloma March 2008 Phase 4
NCT01075425 Virginia Commonwealth University|National Cancer Institute (NCI) Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia May 2010 Phase 1
NCT00440479 Janssen-Cilag B.V. Multiple Myeloma|Hematological Neoplasms September 2006 Phase 4
NCT01830465 Gruppo Italiano Studio Linfomi Non Hodgkin's Follicular Lymphoma August 2006 Phase 2
NCT01383759 Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc. Light Chain Deposition Disease (LCDD or MIDD)|Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)|Monoclonal Immunoglobulin Deposition Disease (MIDD)|Amyloidosis June 24, 2011
NCT00869323 Masonic Cancer Center, University of Minnesota|Millennium Pharmaceuticals, Inc. Lymphoproliferative Disorder March 2009 Phase 2
NCT00103506 Janssen Research & Development, LLC Multiple Myeloma December 2004 Phase 3
NCT02808091 National Cancer Centre, Singapore Extranodal NK-T-CELL LYMPHOMA March 2011 Phase 2
NCT00077428 National Cancer Institute (NCI)|Southwest Oncology Group Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Salivary Gland Adenoid Cystic Carcinoma|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Salivary Gland Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Salivary Gland Cancer June 2004 Phase 2
NCT01242267 Hackensack University Medical Center|Millennium Pharmaceuticals, Inc. Multiple Myeloma April 2010 Phase 1|Phase 2
NCT03130348 Mayo Clinic|National Cancer Institute (NCI) Amyloidosis|Immunoglobulin Light Chain Deposition July 15, 2017 Phase 2
NCT00021216 National Cancer Institute (NCI) Unspecified Childhood Solid Tumor, Protocol Specific November 2001 Phase 1
NCT00151320 Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc. Non-Hodgkin's Lymphoma January 2004 Phase 1|Phase 2
NCT01063179 Fondazione Neoplasie Sangue Onlus Multiple Myeloma May 2006 Phase 3
NCT01633645 University Hospital of Crete Non Small Cell Lung Cancer|Metastatic June 2009 Phase 2
NCT02027220 Second Affiliated Hospital of Soochow University Myeloma|Bortezomib|Cyclophosphamide|Dexamethasone|Granulocyte Colony-Stimulating Factor December 2013 Phase 2
NCT00972959 University of Athens Multiple Myeloma July 2009 Phase 2
NCT00703664 National Cancer Institute (NCI) Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma July 9, 2008 Phase 2
NCT01594242 Abramson Cancer Center of the University of Pennsylvania Multiple Myeloma April 2012 Early Phase 1
NCT00025584 National Cancer Institute (NCI) Recurrent Breast Cancer|Stage IV Breast Cancer August 2001 Phase 2
NCT00227513 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific July 2005 Phase 1
NCT00992446 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Adult Diffuse Large B-Cell Lymphoma|B-Cell Non-Hodgkin Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Non-Hodgkin Lymphoma September 2, 2010 Phase 2
NCT00066625 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific July 2003 Phase 1
NCT01329289 University of Pittsburgh|Novartis Multiple Myeloma in Relapse|Multiple Myeloma December 2011 Phase 2
NCT01965353 Dana-Farber Cancer Institute|Novartis Multiple Myeloma in Relapse October 2013 Phase 1
NCT02026505 Oregon Health and Science University|Millennium: The Takeda Oncology Company Multiple Myeloma|Heart Failure, Systolic|Cardiotoxins March 2014
NCT00553644 National Cancer Institute (NCI) Recurrent Mantle Cell Lymphoma November 2007 Phase 2
NCT00998010 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Brain and Central Nervous System Tumors June 2011 Phase 2
NCT01212952 Mayo Clinic|National Cancer Institute (NCI) Refractory Multiple Myeloma September 2011 Phase 1|Phase 2
NCT00369226 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Millennium Pharmaceuticals, Inc. Hematologic Malignancies August 2006 Phase 1|Phase 2
NCT00473590 Genentech, Inc. Multiple Myeloma June 2007 Phase 2
NCT00401843 Janssen Research & Development, LLC Multiple Myeloma November 28, 2006 Phase 2
NCT00515138 University of California, San Francisco Lymphoma, B-Cell May 2007 Early Phase 1
NCT00262873 University of Rochester Myelodysplastic Syndromes May 2005 Phase 2
NCT00307086 H. Lee Moffitt Cancer Center and Research Institute|Millennium Pharmaceuticals, Inc. Multiple Myeloma|Plasma Cell Leukemia June 2005 Phase 2
NCT00088855 National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma June 15, 2004 Phase 2
NCT00861250 Tampere University Hospital|Turku University Hospital|Oulu University Hospital|Kuopio University Hospital|Helsinki University Central Hospital|Central Hospital of Kanta-Hame|Seinajoki Central Hospital|Jyväskylä Central Hospital|Janssen-Cilag Ltd.|Päijänne Tavastia Central Hospital Multiple Myeloma March 2009 Phase 2|Phase 3
NCT00980395 University of Arizona|National Cancer Institute (NCI) Lymphoma|Mantle Cell Lymphoma|Indolent Lymphoma|SLL July 2009 Phase 2
NCT00958256 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Mantle Cell Lymphoma|Lymphoma August 2009 Phase 2
NCT00994500 National Cancer Institute (NCI) Childhood Burkitt Lymphoma|Childhood Central Nervous System Choriocarcinoma|Childhood Central Nervous System Germ Cell Tumor|Childhood Central Nervous System Germinoma|Childhood Central Nervous System Mixed Germ Cell Tumor|Childhood Central Nervous System Teratoma|Childhood Central Nervous System Yolk Sac Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Medulloepithelioma|Childhood Meningi August 2009 Phase 1
NCT00790647 Boston Medical Center Multiple Myeloma June 2008 Phase 2
NCT01267812 City of Hope Medical Center|National Cancer Institute (NCI) Contiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Stage I Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma August 26, 2011 Phase 2
NCT00548717 Dana-Farber Cancer Institute|Wyeth is now a wholly owned subsidiary of Pfizer|PDL BioPharma, Inc. Graft-vs-Host Disease October 2007 Phase 2
NCT00379574 Asan Medical Center|Janssen Korea, Ltd., Korea Lymphoma, Large-Cell, Diffuse|Lymphoma, B-Cell September 2006 Phase 1|Phase 2
NCT01132911 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Lymphoma|Sarcoma|WilmsTumor|Neuroblastoma May 10, 2010 Phase 1
NCT02290431 Novartis Pharmaceuticals|Novartis Relapse/Refractory Multiple Myeloma December 18, 2014 Phase 2
NCT00024011 National Cancer Institute (NCI) Recurrent Melanoma|Stage IV Melanoma July 2001 Phase 2
NCT00077467 National Cancer Institute (NCI) Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Promyelocytic Leukemia (M3)|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia January 2004 Phase 1
NCT02877082 Emory University Acute Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Graft Versus Host Disease|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Neoplasm|Small Lymphocytic Lymphoma September 2016 Phase 2
NCT02441686 Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.|Celgene Multiple Myeloma December 2015 Phase 2
NCT01063907 Kyowa Hakko Kirin Pharma, Inc.|Kyowa Hakko Kirin Co., Ltd|Kyowa Kirin Pharmaceutical Development, Inc. Multiple Myeloma March 2010 Phase 1|Phase 2
NCT01435395 Emory University|Schering-Plough|Genentech, Inc.|Millennium Pharmaceuticals, Inc. Glioblastoma Multiforme December 2011 Phase 1
NCT00652041 PETHEMA Foundation Multiple Myeloma January 2007 Phase 4
NCT01381692 National Cancer Institute (NCI) Cognitive Side Effects of Cancer Therapy|Fatigue|Neurotoxicity Syndrome|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Therapy-Related Toxicity|Waldenstrom Macroglobulinemia July 20, 2011 Phase 1|Phase 2
NCT00091117 National Cancer Institute (NCI) Hepatic Complications|Malignant Neoplasm July 2004 Phase 1
NCT00103259 National Cancer Institute (NCI) Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squam July 2005 Phase 2
NCT00084747 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm June 2004 Phase 1|Phase 2
NCT00703300 National Cancer Institute (NCI) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia June 2008 Phase 1
NCT01056601 Masonic Cancer Center, University of Minnesota|Novartis Pharmaceuticals|Millennium Pharmaceuticals, Inc. Pancreatic Cancer September 2010 Phase 2
NCT00440635 Janssen-Cilag International NV Multiple Myeloma January 2004
NCT01056276 SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc.|Cephalon Multiple Myeloma May 2010 Phase 2
NCT00544284 City of Hope Medical Center|National Cancer Institute (NCI) Brain and Central Nervous System Tumors|Lymphoma|Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific January 2005 Phase 1
NCT00303797 National Cancer Institute (NCI) Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Stage III Multiple Myeloma|Stage IV Chronic Lymphocytic Leukemia|Unspecified Adult Solid Tumor, Protocol Specific December 2005 Phase 1
NCT01913730 Stichting Hemato-Oncologie voor Volwassenen Nederland|Fondazione Neoplasie Sangue Onlus Multiple Myeloma November 2013 Phase 2
NCT00513877 Cancer Trials Ireland Malignant Mesothelioma May 2006 Phase 2
NCT01002248 AEterna Zentaris|Dana-Farber Cancer Institute Multiple Myeloma December 2009 Phase 3
NCT01174888 Alison Walker|Novartis|Millennium Pharmaceuticals, Inc.|Ohio State University Comprehensive Cancer Center Acute Myeloid Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following|Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia August 2010 Phase 1
NCT01163357 City of Hope Medical Center|National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma January 28, 2011 Phase 1
NCT02109861 Henrik Gregersen|Aalborg Universitetshospital Multiple Myeloma January 2014 Early Phase 1
NCT00839956 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma February 2009 Phase 2
NCT00719901 National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma July 2008 Phase 1|Phase 2
NCT01074411 National Cancer Institute (NCI) Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovar April 5, 2010 Phase 1
NCT01083316 Boston Medical Center|Millennium Pharmaceuticals, Inc. Amyloidosis September 2009 Phase 2
NCT00602511 Nordic Myeloma Study Group Multiple Myeloma October 2007 Phase 3
NCT00624936 Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms April 2008 Phase 1
NCT00311337 University of Wuerzburg Multiple Myeloma October 2005 Phase 2
NCT00813150 Janssen-Cilag G.m.b.H Multiple Myeloma January 2009 Phase 3
NCT00075751 National Cancer Institute (NCI) Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer January 2004 Phase 2
NCT00258245 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm May 2005 Phase 1
NCT00082966 National Cancer Institute (NCI) Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma March 2004 Phase 2
NCT01445405 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer February 5, 2008 Phase 1
NCT00510887 Duke University|Millennium Pharmaceuticals, Inc. Lymphoma, Follicular January 2007 Phase 2
NCT00996385 Columbia University Mesothelioma September 2009 Phase 2
NCT00288041 National Cancer Institute (NCI) Ciliary Body and Choroid Melanoma, Medium/Large Size|Extraocular Extension Melanoma|Iris Melanoma|Recurrent Intraocular Melanoma|Recurrent Melanoma|Stage IV Melanoma October 2005 Phase 2
NCT00641706 National Cancer Institute (NCI) Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor July 2008 Phase 2
NCT01127009 Case Comprehensive Cancer Center Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adul July 2010 Phase 1
NCT00124579 Southwest Oncology Group|National Cancer Institute (NCI) Multiple Myeloma August 2005 Phase 2
NCT00335348 Peter MacCallum Cancer Centre, Australia|Janssen-Cilag Ltd. Multiple Myeloma June 2006 Phase 2
NCT00262860 University of Rochester Lymphoma April 2005 Phase 2
NCT00068315 National Cancer Institute (NCI) Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hematopoietic/Lymphoid Cancer|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia July 2003 Phase 1
NCT00636311 Istituto Clinico Humanitas Hodgkin Disease February 2008 Phase 2
NCT01728259 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Light Chain Deposition Disease|Primary Systemic Amyloidosis March 2013 Phase 1
NCT00096005 National Cancer Institute (NCI) Adult Grade III Lymphomatoid Granulomatosis|AIDS-related Peripheral/Systemic Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurre November 2004 Phase 1
NCT00520767 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Primary Systemic Amyloidosis|Light Chain Deposition Disease September 2007 Phase 2
NCT00547534 University of Rochester|Millennium Pharmaceuticals, Inc.|Cephalon Non-Hodgkin's Lymphoma October 2007 Phase 2
NCT00590603 Duke University|Cephalon Multiple Myeloma July 2008 Phase 1
NCT01950611 Christian Medical College, Vellore, India Relapsed Acute Promyelocytic Leukemia May 2013 Phase 2
NCT00085410 National Cancer Institute (NCI) Adenocarcinoma of the Extrahepatic Bile Duct|Adenocarcinoma of the Gallbladder|Advanced Adult Primary Liver Cancer|Gastrointestinal Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer January 2004 Phase 2
NCT02112916 National Cancer Institute (NCI) Adult T Acute Lymphoblastic Leukemia|Childhood T Acute Lymphoblastic Leukemia|Stage II Childhood Lymphoblastic Lymphoma|Stage II Contiguous Adult Lymphoblastic Lymphoma|Stage II Non-Contiguous Adult Lymphoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia September 30, 2014 Phase 3
NCT00667641 University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Melanoma (Skin)|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific March 2007 Phase 1
NCT01998503 Nanjing University School of Medicine Amyloidosis December 2007 Phase 3
NCT00064012 University of Wisconsin, Madison|National Cancer Institute (NCI) Lung Cancer May 2003 Phase 2
NCT00832234 European Myeloma Network|University of Athens|University of Roma La Sapienza|Niguarda Hospital|University of Turin, Italy|University of Salamanca|Hospital Clinic of Barcelona|Hotel Dieu Hospital|Erasmus Medical Center|University Hospital, Toulouse|IRCCS Policlinico S. Matteo|Laikon General District Hospital, Athens|Klinikum der Universitaet Muenchen, Grosshadern|Aalborg Universitetshospital|Centre Hospitalier de Lens|Universitaire Ziekenhuizen Leuven|Theagenio Cancer Hospital|University of Wuerzburg|Skane University Hospital|Sahlgren´s University Hospital Waldenstroms Macroglobulinemia September 2006 Phase 2
NCT00724568 University of Michigan Cancer Center Multiple Myeloma May 2008 Phase 1|Phase 2
NCT00052338 National Cancer Institute (NCI) Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer September 2002 Phase 1
NCT03117361 PharmaMar Multiple Myeloma November 15, 2016 Phase 2
NCT00108069 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Glioma April 2005 Phase 2
NCT01142401 National Cancer Institute (NCI) Estrogen Receptor Positive|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer May 26, 2010 Phase 2
NCT00243035 National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma August 2005 Phase 1|Phase 2
NCT00863369 City of Hope Medical Center|National Cancer Institute (NCI) Lymphoma June 20, 2005 Phase 1|Phase 2
NCT02371148 Fondazione Italiana Linfomi ONLUS Waldenstrom's Macroglobulinemia June 2014 Phase 2
NCT00038571 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Lymphoma, B-Cell May 2002 Phase 2
NCT02844322 Institute of Hematology & Blood Diseases Hospital Waldenström Macroglobulinemia May 2016 Phase 4
NCT00045695 NCIC Clinical Trials Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group Lymphoma August 2002 Phase 2
NCT01919086 Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc.|Hartford Hospital Multiple Myeloma (MM) August 2013 Phase 2
NCT02082405 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma April 2015 Phase 2
NCT00510939 University of Bologna|Janssen-Cilag Ltd. Acute Myeloid Leukemia March 2007 Phase 2
NCT00411905 Groupe Francophone des Myelodysplasies Myelodysplastic Syndromes June 2006 Phase 1|Phase 2
NCT00028587 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific December 2001 Phase 1
NCT00411593 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.|Genentech, Inc. Lung Cancer November 2006 Phase 1|Phase 2
NCT02375555 Dana-Farber Cancer Institute|Bristol-Myers Squibb Multiple Myeloma May 2015 Phase 2
NCT00431990 Peter MacCallum Cancer Centre, Australia|Celgene Corporation|Janssen-Cilag Ltd. Multiple Myeloma November 2006 Phase 1|Phase 2
NCT01206205 University Hospital, Toulouse|Celgene Corporation|Janssen-Cilag Ltd. Multiple Myeloma August 2009 Phase 2
NCT01439750 Milton S. Hershey Medical Center Mantle Cell Lymphoma May 2012 Phase 1|Phase 2
NCT01531998 M.D. Anderson Cancer Center|Janssen Services, LLC Myeloma May 2012 Phase 1|Phase 2
NCT02489500 Boston Medical Center AL Amyloidosis June 2015 Phase 3
NCT00629226 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Head and Neck Cancer October 2007 Phase 1
NCT02718833 Massachusetts General Hospital|Celgene|Bristol-Myers Squibb|Multiple Myeloma Research Consortium Multiple Myeloma June 2016 Phase 2
NCT01504776 Anand Jillella|Novartis Pharmaceuticals|Augusta University Mantle Cell Lymphoma April 2011 Phase 1
NCT01078961 Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Bayer|Millennium Pharmaceuticals, Inc. Melanoma September 2010 Phase 1
NCT00511069 University of Bologna Leukemia July 2006 Phase 2
NCT00407303 Gemin X|Teva Pharmaceutical Industries Mantle-Cell Lymphoma October 2006 Phase 1|Phase 2
NCT00744354 UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp.|Millennium Pharmaceuticals, Inc.|Ortho Biotech, Inc. Multiple Myeloma and Plasma Cell Neoplasm October 2008 Phase 1
NCT01349595 Mark Stegall|Millennium Pharmaceuticals, Inc.|Mayo Clinic Disorder of Transplanted Kidney December 2011 Phase 2
NCT01078454 National Cancer Institute (NCI) Light Chain Deposition Disease|Primary Systemic Amyloidosis November 2010 Phase 3
NCT01300793 University of California, San Francisco|Millennium Pharmaceuticals, Inc. Non-Hodgkin's Lymphoma|B-cell Lymphoma May 2007 Phase 1
NCT00378105 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc. Multiple Myeloma September 2006 Phase 1|Phase 2
NCT00080405 Millennium Pharmaceuticals, Inc. Multiple Myeloma March 2004 Phase 1
NCT02874742 Janssen Research & Development, LLC Multiple Myeloma August 29, 2016 Phase 2
NCT00378209 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc. Multiple Myeloma August 2006 Phase 2
NCT00193557 SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc. Multiple Myeloma May 2004 Phase 2
NCT00401804 Austrian Forum Against Cancer Multiple Myeloma|Renal Insuficiency February 2006 Phase 2
NCT00469209 M.D. Anderson Cancer Center|Cephalon Myeloma June 2006 Phase 1|Phase 2
NCT02514382 University of Southern California|National Cancer Institute (NCI)|Oncolytics Biotech Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma August 21, 2015 Phase 1
NCT00107341 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Esophageal Cancer August 2005 Phase 2
NCT01072773 Mayo Clinic Primary Systemic Amyloidosis March 2010 Phase 2
NCT01788020 University of Ulm Waldenström's Macroglobulinemia November 2013 Phase 3
NCT00358020 University of Turin, Italy Multiple Myeloma November 2004 Phase 2
NCT02353468 University of Colorado, Denver Refractory Plasma Cell Myeloma December 2009 Phase 2
NCT01324596 University Hospital Southampton NHS Foundation Trust|Janssen-Cilag Ltd. Lymphoma, Large B-Cell, Diffuse April 2011 Phase 3
NCT02559154 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Multiple Myeloma July 2010 Phase 4
NCT00027898 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific January 2002 Phase 1
NCT00291538 Nantes University Hospital Multiple Myeloma February 2006 Phase 1
NCT00858234 Merck Sharp & Dohme Corp. Multiple Myeloma March 2009 Phase 1
NCT01668719 Southwest Oncology Group|National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma November 2012 Phase 1|Phase 2
NCT00329589 Sidney Kimmel Cancer Center at Thomas Jefferson University|Millennium Pharmaceuticals, Inc.|Thomas Jefferson University Brain Cancer|Head and Neck Cancer|Cervix Cancer|Central Nervous System Neoplasms September 2005 Phase 1
NCT00428142 NCIC Clinical Trials Group|Canadian Cancer Trials Group Lymphoma December 2006 Phase 2
NCT00507416 Millennium Pharmaceuticals, Inc. Multiple Myeloma June 2007 Phase 3
NCT01449344 Prof. Dr. M. Dreyling (co-chairman)|Klinikum der Universitaet Muenchen, Grosshadern|ClinAssess GmbH|GELARC Service de Pharmacovigilance, Pierre Benite|European Mantle Cell Lymphoma Network Mantle Cell Lymphoma May 9, 2009 Phase 3
NCT01208662 Paul G. Richardson, MD|Celgene Corporation|Millennium Pharmaceuticals, Inc.|Massachusetts General Hospital|Cape Cod Healthcare|Beth Israel Deaconess Medical Center|Emory University|University of Michigan|Fox Chase Cancer Center|Memorial Sloan Kettering Cancer Center|Fred Hutchinson Cancer Research Center|Barbara Ann Karmanos Cancer Institute|Duke University|University of California, San Francisco|University of Chicago|M.D. Anderson Cancer Center|UNC Lineberger Comprehensive Cancer Center|Roswell Park Cancer Institute|Stanford University|University of Mississippi Medical Center|Icahn School of Medicine at Mount Sinai|Wake Forest University Health Sciences|University of Arizona|OHSU Knight Cancer Institute|Eastern Maine Medical Center|University of California, San Diego|University of Alabama at Birmingham|University of Pittsburgh|Ochsner Health System|University of Texas Southwestern Medical Center|State University of New York - Downstate Medical Center|Newton-Wellesley Hospital|Baylor College of Medicine|City of Hope Medical Center|University of Florida|Northwell Health|H. Lee Moffitt Cancer Center and Research Institute|Vanderbilt University Medical Center|Ohio State University|Huntsman Cancer Institute|Columbia University|Dana-Farber Cancer Institute Multiple Myeloma September 2010 Phase 3
NCT02755597 AbbVie|Genentech, Inc. Relapsed/Refractory Multiple Myeloma July 11, 2016 Phase 3
NCT00280176 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) Colorectal Cancer April 2003 Phase 1
NCT01769209 Stanford University|National Cancer Institute (NCI) B-cell Adult Acute Lymphoblastic Leukemia|Ph Positive Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia March 2013 Phase 2
NCT00007878 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific September 2000 Phase 1
NCT00416793 National Cancer Institute (NCI) Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Stage IV Pancreatic Cancer December 2006 Phase 2
NCT00522392 National Cancer Institute (NCI) Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma September 2007 Phase 3
NCT00708292 Novartis Pharmaceuticals|Novartis Relapsed or Refractory Multiple Myeloma July 2008 Phase 1|Phase 2
NCT01539083 Janssen Scientific Affairs, LLC Multiple Myeloma January 13, 2012 Phase 3
NCT00082784 National Cancer Institute (NCI) Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Plasma Cell Myeloma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglo March 2004 Phase 1
NCT00531453 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Multiple Myeloma October 2007 Phase 2
NCT00052689 National Cancer Institute (NCI) Duct Cell Adenocarcinoma of the Pancreas|Stage IV Pancreatic Cancer December 2002 Phase 2
NCT03201965 Janssen Research & Development, LLC Amyloidosis September 1, 2017 Phase 3
NCT01453101 Hackensack University Medical Center Multiple Myeloma June 9, 2010 Phase 2
NCT02783625 Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|Stanford University Lymphoma|Relapsed/Refractory T-cell Lymphomas May 2016 Phase 1
NCT01794507 AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie Relapsed/Refractory Multiple Myeloma November 26, 2012 Phase 1
NCT00564200 PETHEMA Foundation Multiple Myeloma November 2007 Phase 2
NCT01863004 University Hospital, Basel, Switzerland Dysferlinopathy December 2012 Phase 1
NCT00362882 National Cancer Institute (NCI) Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer July 2006 Phase 2
NCT00555906 Pfizer Multiple Myeloma January 2008 Phase 2
NCT01936090 Mayo Clinic|National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma August 2013 Phase 1|Phase 2
NCT01537861 Washington University School of Medicine Multiple Myeloma June 2012 Early Phase 1
NCT00030875 NCIC Clinical Trials Group|Canadian Cancer Trials Group Lymphoma July 2002 Phase 2
NCT01706666 Mayo Clinic Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma December 2012 Phase 2
NCT00148018 University of Cologne|German Hodgkin's Lymphoma Study Group|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Hodgkin Disease March 2005 Phase 2
NCT00052507 University Health Network, Toronto|National Cancer Institute (NCI) Colorectal Cancer January 2003 Phase 2
NCT00027716 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Sarcoma October 2001 Phase 2
NCT00967369 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Hodgkin's Lymphoma August 2009 Phase 2
NCT01078441 National Cancer Institute (NCI) Refractory Multiple Myeloma September 2010 Phase 2
NCT00644228 National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma April 2008 Phase 3
NCT00118183 National Cancer Institute (NCI) Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Large Cell Lung Cancer|Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer July 2005 Phase 2
NCT00066508 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Lymphoma May 2003 Phase 2
NCT00458822 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm February 2007 Phase 2
NCT02474563 Janssen Korea, Ltd., Korea Multiple Myeloma May 2011 Phase 4
NCT00068484 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific July 2003 Phase 1
NCT00210392 International Extranodal Lymphoma Study Group (IELSG) Lymphoma, Mucosa-Associated Lymphoid Tissue July 2005 Phase 2
NCT01592981 University College, London Waldenstrom's Macroglobulinaemia January 2013 Phase 2
NCT00066352 University Health Network, Toronto|National Cancer Institute (NCI) Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter September 2003 Phase 2
NCT00093756 National Cancer Institute (NCI) Recurrent Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer September 2004 Phase 1|Phase 2
NCT00666588 National Cancer Institute (NCI) Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Childhood Acute Basophilic Leukemia|Childhood Acute Eosinophilic April 2008 Phase 2
NCT00074009 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Gastric Cancer October 2003 Phase 2
NCT00114738 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Lymphoma, Mantle Cell|Mantle Cell Lymphoma June 15, 2005 Phase 2
NCT00290680 Medical University of South Carolina Unspecified Adult Solid Tumor, Protocol Specific March 2005 Phase 1
NCT00068289 Southwest Oncology Group|National Cancer Institute (NCI) Lung Cancer September 2003 Phase 2
NCT00504101 University of Miami Multiple Myeloma and Plasma Cell Neoplasm June 2007 Phase 1
NCT00513955 Plymouth Hospitals NHS Trust Lymphoma June 2006 Phase 2
NCT01910987 Janssen-Cilag International NV Multiple Myeloma April 2013 Phase 3
NCT00377052 NCIC Clinical Trials Group|Canadian Cancer Trials Group Lymphoma June 2006 Phase 2
NCT00440726 Therapeutic Advances in Childhood Leukemia Consortium Acute Lymphoblastic Leukemia June 2006 Phase 1|Phase 2
NCT00458913 European Organisation for Research and Treatment of Cancer - EORTC Malignant Mesothelioma February 2007 Phase 2
NCT02522572 E. Steve Woodle|Sanofi-Synthelabo|University of Cincinnati Transplants and Implants August 2015 Phase 1|Phase 2
NCT00750815 H. Lee Moffitt Cancer Center and Research Institute|Millennium Pharmaceuticals, Inc.|Ortho Biotech, Inc. Multiple Myeloma September 2008 Phase 1|Phase 2
NCT00388089 University of California, Davis|National Cancer Institute (NCI) Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific December 2004 Phase 1
NCT00028912 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer November 2001 Phase 1
NCT02542111 Ruijin Hospital Diffuse Large B-cell Lymphoma May 2015 Phase 2
NCT00316940 Oncotherapeutics|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm December 2005 Phase 1
NCT00129207 Millennium Pharmaceuticals, Inc. Tumors Phase 1
NCT01286272 National Cancer Institute (NCI) Grade 3a Follicular Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma April 8, 2011 Phase 2
NCT00740415 French Innovative Leukemia Organisation|Janssen, LP|Mundipharma Pte Ltd. Lymphoma June 2007 Phase 2
NCT01191060 University Hospital, Toulouse|Dana-Farber Cancer Institute|Celgene Corporation|Janssen-Cilag Ltd. Myeloma October 2010 Phase 3
NCT00425750 Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) Head and Neck Cancer August 2005 Phase 2
NCT00381940 National Cancer Institute (NCI) Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Childhood Lymphocyte Depletion Hodgkin Lymphoma|Childhood Lymphocyte Predominant Hodgkin Lymphoma|Childhood Mixed Cellularity Hodgkin Lymphoma|Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Childhood Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymp January 2007 Phase 2
NCT00257114 Millennium Pharmaceuticals, Inc. Multiple Myeloma Phase 4
NCT01332617 James Graham Brown Cancer Center Myeloma April 2011 Phase 2
NCT01605032 Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma February 2012 Phase 2
NCT00541359 City of Hope Medical Center Unspecified Adult Solid Tumor, Protocol Specific January 2004 Phase 1
NCT00799539 Janssen-Ortho Inc., Canada|Ortho Biotech Canada Multiple Myeloma
NCT00023881 M.D. Anderson Cancer Center|National Cancer Institute (NCI) Leukemia July 2001 Phase 2
NCT01522872 Threshold Pharmaceuticals Multiple Myeloma February 2012 Phase 1|Phase 2
NCT00884546 Bristol-Myers Squibb|Exelixis Advanced Cancer, Various, NOS July 2009 Phase 1
NCT00571493 University of Nebraska|Millennium Pharmaceuticals, Inc. Non-hodgkin's Lymphoma|Mantle Cell Lymphoma April 2006 Phase 1|Phase 2
NCT02513186 Sanofi Plasma Cell Myeloma September 30, 2015 Phase 1
NCT00366106 Accelerated Community Oncology Research Network|Millennium Pharmaceuticals, Inc. Multiple Myeloma July 2006 Phase 2
NCT01782963 Massachusetts General Hospital Multiple Myeloma March 2013 Phase 2
NCT00216697 Janssen Pharmaceutical K.K. Multiple Myeloma March 2005 Phase 2
NCT00514371 Bristol-Myers Squibb Multiple Myeloma August 2007 Phase 2|Phase 3
NCT00849251 University of Washington|National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma November 2008 Phase 1|Phase 2
NCT01312818 Masonic Cancer Center, University of Minnesota|Millennium Pharmaceuticals, Inc. Acute Lymphoblastic Leukemia June 2011 Phase 2
NCT00706953 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Centocor Ortho Biotech Services, L.L.C. Multiple Myeloma July 2008 Phase 2
NCT01313897 University of Arkansas|National Institutes of Health (NIH) Multiple Myeloma January 2011 Phase 2
NCT01769443 National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation Primary Heart Transplant|Heart Transplantation|Heart Transplant June 2013 Phase 2
NCT00389701 Sparrow Regional Cancer Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm March 2006 Phase 2
NCT00193232 SCRI Development Innovations, LLC|Aventis Pharmaceuticals|Millennium Pharmaceuticals, Inc. Prostate Cancer May 2004 Phase 2
NCT02484261 Reuven Schore|Millennium Pharmaceuticals, Inc.|Hyundai Hope On Wheels|Children's Research Institute Leukemia May 2015 Phase 1
NCT01478048 Bristol-Myers Squibb|AbbVie Multiple Myeloma November 2011 Phase 2
NCT00098982 European Organisation for Research and Treatment of Cancer - EORTC Colorectal Cancer September 2004 Phase 1
NCT00561743 Janssen-Ortho Inc., Canada Multiple Myeloma November 2005 Phase 2
NCT01534143 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma February 2012 Phase 2
NCT00312845 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Non-Hodgkin's Lymphoma March 2006 Phase 3
NCT00458705 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm November 2006 Phase 2
NCT00598169 AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation Lymphoma November 2007 Phase 1
NCT01394354 University Hospital Freiburg|Merck Sharp & Dohme Corp.|Janssen-Cilag Ltd. Multiple Myeloma in Relapse August 2011 Phase 1|Phase 2
NCT01359657 Bristol-Myers Squibb Multiple Myeloma September 2011 Phase 1
NCT00295932 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|Columbia University|Emory University Leukemia|Lymphoma December 2005 Phase 1|Phase 2
NCT00298779 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Tumors|Non-Hodgkins's Lymphoma Phase 1
NCT01177683 Sherif Farag, MB, BS|Hoosier Cancer Research Network|Cephalon Multiple Myeloma July 2010 Phase 1|Phase 2
NCT00441168 Janssen-Cilag International NV Multiple Myeloma December 2006 Phase 2
NCT02605356 Bayer Multiple Myeloma October 2016 Phase 1|Phase 2
NCT02424851 Oxford University Hospitals NHS Trust|Janssen-Cilag Ltd.|Bloodwise|University of Warwick|University of Birmingham Multiple Myeloma|Chronic Kidney Disease November 2014 Phase 2
NCT00523848 Roswell Park Cancer Institute Multiple Myeloma and Plasma Cell Neoplasm June 2006 Phase 2
NCT00361621 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Millennium Pharmaceuticals, Inc. Non-Hodgkin's Lymphoma July 2006 Phase 2
NCT01863550 ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma November 2013 Phase 3
NCT02419755 St. Jude Children's Research Hospital Mixed Lineage Acute Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia April 2015 Phase 2
NCT00317811 Oncotherapeutics|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm November 2005 Phase 2
NCT00006098 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes April 2000 Phase 1
NCT02955810 National University of Ireland, Galway, Ireland|Janssen Pharmaceuticals|Cancer Trials Ireland Multiple Myeloma November 2016 Phase 1
NCT00184015 University of Southern California Renal Cell Cancer August 18, 2005 Phase 1|Phase 2
NCT00948922 H. Lee Moffitt Cancer Center and Research Institute|Millennium Pharmaceuticals, Inc. Multiple Myeloma June 18, 2009 Phase 2
NCT00210327 International Extranodal Lymphoma Study Group (IELSG) Lymphoma, Mucosa-Associated Lymphoid Tissue July 2005 Phase 2
NCT00792142 City of Hope Medical Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm|Neurotoxicity January 2008 Phase 2
NCT01386398 European Organisation for Research and Treatment of Cancer - EORTC Lymphoma Phase 3
NCT01554852 University of Leeds|Celgene|Merck Sharp & Dohme Corp.|Amgen Multiple Myeloma May 2010 Phase 3
NCT00436059 Vejle Hospital|Odense University Hospital Multiple Myeloma February 2007 Phase 2
NCT01754389 Dana-Farber Cancer Institute Graft Versus Host Disease January 2013 Phase 2
NCT00028639 Northwestern University|National Cancer Institute (NCI) Breast Cancer August 2001 Phase 2
NCT00546780 Bristol-Myers Squibb Multiple Myeloma February 2008 Phase 3
NCT00111319 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Multiple Myeloma December 2004 Phase 3
NCT00004002 New York University School of Medicine|National Cancer Institute (NCI) Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific July 1999 Phase 1
NCT00017199 Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) Gastrointestinal Carcinoid Tumor|Islet Cell Tumor April 2001 Phase 2
NCT00017329 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Kidney Cancer April 2001 Phase 2
NCT01248923 Array BioPharma Multiple Myeloma, Plasma Cell Leukemia December 2010 Phase 1
NCT00609167 Mayo Clinic|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm December 2006 Phase 2
NCT01916252 PETHEMA Foundation|Janssen, LP|Celgene|Pierre Fabre Medicament Multiple Myeloma September 2013 Phase 3
NCT00334932 Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm February 2006 Phase 1|Phase 2
NCT00931918 Millennium Pharmaceuticals, Inc.|Takeda Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) October 2009 Phase 2
NCT00256776 European Group for Blood and Marrow Transplantation|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Celgene Corporation Multiple Myeloma July 2005 Phase 3
NCT00389805 University of California, Davis|Eli Lilly and Company Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific March 2005 Phase 1|Phase 2
NCT00711828 Mayo Clinic|National Cancer Institute (NCI) Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia August 2008 Phase 2
NCT01954784 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma October 7, 2013 Phase 1
NCT02654990 Novartis Pharmaceuticals|Novartis Multiple Myeloma April 27, 2016 Phase 2
NCT00063726 Millennium Pharmaceuticals, Inc. Multiple Myeloma April 2002 Phase 3
NCT00006362 Mayo Clinic|National Cancer Institute (NCI) Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific November 1999 Phase 1
NCT01216683 Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Lymphoma December 2010 Phase 2
NCT00103103 California Cancer Consortium|National Cancer Institute (NCI) Gastric Cancer March 2005 Phase 2
NCT01647165 National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.|National Institutes of Health Clinical Center (CC) Multiple Myeloma July 11, 2012 Phase 2
NCT00478075 Mayo Clinic|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm September 2005 Phase 1|Phase 2
NCT00568880 University of Pennsylvania|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm November 2007 Phase 1|Phase 2
NCT01685814 Wuerzburg University Hospital|ClinAssess GmbH|Celgene Corporation Previously Untreated Symptomatic Multiple Myeloma May 2012 Phase 3
NCT01848132 Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Janssen-Cilag, S.A. Diffuse, Large B-Cell, Lymphoma October 3, 2013 Phase 2
NCT00063791 Millennium Pharmaceuticals, Inc. Multiple Myeloma
NCT00063713 Millennium Pharmaceuticals, Inc. Mantle Cell Lymphoma June 2003 Phase 2
NCT01371981 National Cancer Institute (NCI) Leukemia Cutis|Myeloid Sarcoma|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Myeloid Neoplasm June 20, 2011 Phase 3
NCT01484626 Loyola University Multiple Myeloma May 2011 Phase 1|Phase 2
NCT00048230 Millennium Pharmaceuticals, Inc. Multiple Myeloma June 2002 Phase 3
NCT02362165 Sun Yat-sen University Multiple Myeloma April 2015 Phase 3
NCT00103376 Medical University of South Carolina Prostate Cancer October 2004 Phase 2
NCT01415752 Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Lymphoma|Neurotoxicity|Therapy-related Toxicity May 2012 Phase 2
NCT00148317 Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc. Multiple Myeloma June 2005 Phase 2
NCT00908232 Janssen-Cilag International NV Multiple Myeloma May 2008 Phase 2
NCT01208766 Stichting Hemato-Oncologie voor Volwassenen Nederland|European Myeloma Network|GIMEMA (Italian Group for Adult Hematologic Diseases)|DSMM (Deutsche Studiengruppe Multiples Myelom)|NMSG (Nordic Myeloma Study Group)|Central European Myeloma Study Group Multiple Myeloma January 2011 Phase 3
NCT00507442 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Multiple Myeloma August 2007 Phase 1|Phase 2
NCT01420926 National Cancer Institute (NCI) Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myelo November 2011 Phase 2
NCT00011778 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Squamous Cell Carcinoma February 22, 2001 Phase 1
NCT00911859 Janssen Research & Development, LLC Multiple Myeloma June 2009 Phase 2
NCT00051974 Millennium Pharmaceuticals, Inc. Non-Small Cell Lung Cancer December 2002 Phase 2
NCT00051987 Millennium Pharmaceuticals, Inc. Colorectal Carcinoma December 2002 Phase 2
NCT00064636 Millennium Pharmaceuticals, Inc. Advanced Non-Small Cell Lung Cancer|Other Solid Tumors December 2002 Phase 1
NCT02219178 Cancer Trials Ireland Multiple Myeloma November 2014 Phase 2
NCT00610792 Millennium Pharmaceuticals, Inc. Ovarian Cancer July 2006 Phase 2
NCT00265928 University of Virginia|National Cancer Institute (NCI) Lymphoma Phase 2
NCT00873093 National Cancer Institute (NCI) B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia March 2009 Phase 2
NCT00793572 Fred Hutchinson Cancer Research Center|Millennium Pharmaceuticals, Inc.|National Cancer Institute (NCI) Refractory Plasma Cell Myeloma October 2008 Phase 2
NCT00742404 Oncotherapeutics|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm July 2008 Phase 2
NCT00772668 University of Miami Lymphoma September 2008
NCT00064610 Millennium Pharmaceuticals, Inc. Prostatic Neoplasms December 2002 Phase 1|Phase 2
NCT00438841 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm August 2006 Phase 2
NCT02541383 Intergroupe Francophone du Myelome|HOVON - Dutch Haemato-Oncology Association|Janssen Research & Development, LLC Multiple Myeloma September 2015 Phase 3
NCT01249690 Second Military Medical University|Zhejiang University|Peking University People's Hospital|Fourth Military Medical University|Xiangya Hospital of Central South University|Institute of Hematology & Blood Diseases Hospital|Union hospital of Fujian Medical University|Harbin Hematology and Oncology Institute|First Affiliated Hospital, Sun Yat-Sen University|Beijing Jishuitan Hospital Multiple Myeloma June 2010 Phase 4
NCT00217503 National Cancer Institute (NCI) Lymphoma July 2005 Phase 2
NCT00023855 University of Wisconsin, Madison|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific June 2001 Phase 1
NCT00106262 Women and Infants Hospital of Rhode Island|Millennium Pharmaceuticals, Inc. Cervical Cancer March 2005 Phase 2
NCT01000285 Washington University School of Medicine Leukemia-Lymphoma, Adult T-Cell September 2010 Phase 1|Phase 2
NCT00095680 Scios, Inc. Multiple Myeloma November 2004 Phase 2
NCT02928029 Bayer Multiple Myeloma February 10, 2017 Phase 1|Phase 2
NCT01548573 University of Iowa|National Cancer Institute (NCI) Multiple Myeloma May 2012 Phase 2
NCT01460420 European Myeloma Network Hematologic Malignancies|Multiple Myeloma November 2011 Phase 1|Phase 2
NCT00851552 Roswell Park Cancer Institute|Ortho Biotech, Inc. Lymphoma January 2009 Phase 2
NCT00313690 University of Southern California Lung Cancer April 2006 Phase 1|Phase 2
NCT02951819 Janssen Scientific Affairs, LLC Multiple Myeloma November 9, 2016 Phase 2
NCT00283634 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NSCLC August 2005 Phase 2
NCT00814541 Cancer Trials Ireland Multiple Myeloma and Plasma Cell Neoplasm December 2005 Phase 2
NCT02481934 Joaquín Martínez López, MD, PhD|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Hospital Universitario 12 de Octubre Multiple Myeloma March 2013 Phase 1
NCT00609817 La Jolla Pharmaceutical Company Multiple Myeloma May 2008 Phase 1
NCT00995059 Mayo Clinic Multiple Myeloma|Refractory Multiple Myeloma Phase 1|Phase 2
NCT01556438 Eli Lilly and Company Multiple Myeloma July 2012 Phase 1
NCT00871546 Merck Sharp & Dohme Corp. Lymphoma, Mantle-Cell|Leukemia, Lymphocytic, Chronic, B-Cell March 2009 Phase 2
NCT01653418 Washington University School of Medicine Multiple Myeloma September 2012 Phase 2
NCT02086942 Yongping Zhai|Jinling Hospital, China Multiple Myeloma August 2013 Phase 2
NCT01481194 Vejle Hospital|The University of Hong Kong Multiple Myeloma November 2011 Phase 2
NCT00634179 Emory University|Millennium Pharmaceuticals, Inc. Lymphoma, B-Cell|Follicular Lymphoma February 2008 Phase 1|Phase 2
NCT03000634 University of Arkansas Multiple Myeloma May 2017 Phase 2
NCT02518750 St. Jude Children's Research Hospital|Novartis Pharmaceuticals|Spectrum Pharmaceuticals, Inc Acute Lymphoblastic Leukemia|Lymphoma, Non-Hodgkin's|Leukemia, T-Cell|Leukemia, B-Cell November 23, 2016 Phase 2
NCT01602224 Eli Lilly and Company Multiple Myeloma July 2012 Phase 2
NCT01250808 Peking University Multiple Myeloma
NCT00723658 Southwest Oncology Group|National Cancer Institute (NCI) Lymphoma September 2008 Phase 2
NCT00261612 Medical University of Vienna Lymphoma, Mantle-Cell January 2005 Phase 2
NCT02352558 Boston Biomedical, Inc Hematologic Malignancy May 2015 Phase 1
NCT01109004 National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI) Multiple Myeloma May 2010 Phase 3
NCT02500251 E. Steve Woodle|GlaxoSmithKline|University of Cincinnati Renal Transplant Rejection June 2015 Phase 1|Phase 2
NCT01114048 Chonnam National University Hospital Multiple Myeloma March 2010 Phase 2
NCT01055301 Southwest Oncology Group|National Cancer Institute (NCI) Multiple Myeloma|Plasma Cell Myeloma July 2011 Phase 2
NCT01146834 Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc. Multiple Myeloma March 2011 Phase 3
NCT02495922 University of Heidelberg Medical Center Multiple Myeloma June 2015 Phase 3
NCT00908583 University of Cincinnati|Millennium Pharmaceuticals, Inc. HLA Sensitization May 2009 Phase 4
NCT03188172 University of Leeds|Myeloma UK|Celgene|Janssen, LP Multiple Myeloma July 1, 2017 Phase 2
NCT03168100 University of Arkansas Multiple Myeloma July 2017 Phase 2
NCT02563340 First Affiliated Hospital, Sun Yat-Sen University|Second Affiliated Hospital of Guangzhou Medical University Kidney Transplantation November 2015 Phase 1|Phase 2
NCT00581776 University of Wisconsin, Madison Mantle Cell Lymphoma May 2005 Phase 2
NCT02343042 Karyopharm Therapeutics Inc Multiple Myeloma October 2015 Phase 1|Phase 2
NCT00504751 Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc. Non-Hodgkin's Lymphoma May 2007 Phase 2
NCT01556347 Providence Health & Services Heart Transplantation July 2012 Phase 2
NCT00087867 Scios, Inc. Multiple Myeloma June 2004 Phase 2
NCT00433537 National Cancer Institute (NCI) Contiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Stage I Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma May 2007 Phase 2
NCT01208818 Assistance Publique - Hôpitaux de Paris Chronic Renal Failure With Uremic Nephropathy June 2011 Phase 3
NCT02553460 St. Jude Children's Research Hospital|Gateway for Cancer Research|Texas Children's Hospital Acute Lymphoblastic Leukemia January 29, 2016 Phase 1|Phase 2
NCT01408797 Fuzhou General Hospital|Terasaki Foundation Renal Transplantation|Uremia March 2011 Phase 1|Phase 2
NCT00771875 University of Cincinnati Graft Rejection September 2008 Phase 2
NCT02208037 National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI) Acute Leukemia|Chronic Myelogenous Leukemia|Myelodysplasia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Hodgkin's Lymphoma August 2014 Phase 2
NCT02440464 National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program Multiple Myeloma August 2015 Phase 2
NCT02666209 Dana-Farber Cancer Institute|Bristol-Myers Squibb Multiple Myeloma in Relapse|Multiple Myeloma
NCT03117751 St. Jude Children's Research Hospital|Bristol-Myers Squibb|Incyte Corporation|Shire Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma March 29, 2017 Phase 2|Phase 3
NCT02559778 Giselle Sholler|Dell, Inc.|Beat NB Cancer Foundation|Because of Ezra|Spectrum Health Hospitals Neuroblastoma September 2015 Phase 1
NCT01849783 University of Iowa|National Cancer Institute (NCI) Extramedullary Plasmacytoma|Isolated Plasmacytoma of Bone|Light Chain Deposition Disease|Primary Systemic Amyloidosis|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma April 2013 Phase 2
NCT01350232 Sidney Kimmel Cancer Center at Thomas Jefferson University|National Heart, Lung, and Blood Institute (NHLBI)|Thomas Jefferson University Sickle Cell Anemia|Sickle Cell-hemoglobin C Disease|Sickle Cell-β0-thalassemia September 2009
NCT00092222 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Lymphoproliferative Disorder|HHV-8|Malignancy|HIV September 17, 2004 Phase 2
NCT02719613 Bristol-Myers Squibb|AbbVie Multiple Myeloma July 11, 2016 Phase 2
NCT02057380 Astellas Pharma Global Development, Inc.|Astellas Pharma Inc Advanced Solid Tumors April 2014 Phase 2
NCT01088048 Gilead Sciences Indolent Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma April 2010 Phase 1
NCT03004287 University of Arkansas|Janssen, LP Multiple Myeloma July 1, 2017 Phase 2
NCT02525172 National Taiwan University Hospital Pompe Disease August 2015 Phase 4
NCT02265510 Incyte Corporation Advanced Cancer August 2014 Phase 1|Phase 2
NCT00006184 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Multiple Myeloma August 2000 Phase 2
NCT00276744 Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI) Pancreatic Cancer October 2005 Phase 2
NCT00408928 Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University Graft-versus-Host Disease November 2005 Phase 2
NCT01929980 Children's Hospital Medical Center, Cincinnati Allogeneic Stem Cell Transplantation|Refractory Autoimmune Cytopenia(s) July 2012 Phase 2
NCT00644696 University of Michigan Cancer Center|Millennium Pharmaceuticals, Inc. Neuroblastoma April 2008 Phase 1
NCT01163786 Northwestern University|Robert H. Lurie Cancer Center Bronchiolitis Obliterans July 2010 Phase 2
NCT01090921 Boston VA Research Institute, Inc.|Millennium Pharmaceuticals, Inc. Multiple Myeloma May 2007 Phase 2
NCT01801436 Johnson & Johnson Taiwan Ltd Multiple Myeloma December 2006 Phase 3
NCT00657553 University of Arkansas Multiple Myeloma February 2008 Phase 3
NCT01672229 University of California, Davis|Millennium Pharmaceuticals, Inc. Graft Versus Host Disease July 2012 Phase 1
NCT03013114 Shandong University Immune Thrombocytopenia January 2017 Phase 2
NCT02268890 Johnson & Johnson Taiwan Ltd Multiple Myeloma December 2014 Phase 4
NCT01158105 Baylor Research Institute|Millennium Pharmaceuticals, Inc. Chronic Graft-versus-host Disease June 2010 Phase 2
NCT01328236 Clinical Service, China|Harbin Hematology and Oncology Institute|Shanghai Changzheng Hospital|Chinese PLA General Hospital|307 Hospital of PLA|Wuhan Union Hospital, China|Beijing Chao Yang Hospital|Henan Provincial Hospital|Peking University Third Hospital Plasma Cell Leukemia|Multiple Myeloma September 2010 Phase 2
NCT01517724 University College, London Multiple Myeloma December 2009 Phase 2
NCT00153933 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|H. Lee Moffitt Cancer Center and Research Institute Refractory Multiple Myeloma|Relapsed Multiple Myeloma|Multiple Myeloma August 2004 Phase 1
NCT02102594 Charite University, Berlin, Germany|Prof. Dr. med. Falk Hiepe (Charité, Internal Medicine / Rheumathology)|NeuroCure Clinical Research Center - Charité (Berlin) Myasthenia Gravis|Systemic Lupus Erythematosus|Rheumatoid Arthritis October 2014 Phase 2
NCT03103555 Mahidol University|Ministry of Health, Thailand Adult-onset Immunodeficiency February 27, 2017 Phase 2
NCT00093704 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Lymphoma|Lymphoproliferative Disorder March 2005 Phase 1
NCT00815919 Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc. Chronic Graft Versus Host Disease December 2008 Phase 2
NCT00789256 Dartmouth-Hitchcock Medical Center|Millennium Pharmaceuticals, Inc. Acute Myelogenous Leukemia|Myelodysplastic Syndromes September 2004
NCT00153920 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Brigham and Women's Hospital|Roswell Park Cancer Institute|Emory University|Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc. Multiple Myeloma December 2003 Phase 2
NCT01695330 Oncotherapeutics|Millennium Pharmaceuticals, Inc. Multiple Myeloma May 2012 Phase 2
NCT01965977 Samsung Medical Center|Janssen, LP Diffuse Large B Cell Lymphoma July 2013 Phase 2
NCT02254551 SCRI Development Innovations, LLC|Novartis Multiple Myeloma January 2015 Phase 2
NCT02308280 Maisonneuve-Rosemont Hospital Multiple Myeloma|High-Risk Cancer November 2014 Phase 2
NCT00622674 Masonic Cancer Center, University of Minnesota Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Pancreatic Cancer|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific November 2005 Phase 1
NCT01902862 Janssen-Cilag G.m.b.H Lymphoma, Follicular February 2006 Phase 2
NCT00620295 Masonic Cancer Center, University of Minnesota Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Sarcoma March 2007 Phase 1
NCT00581360 University of Pittsburgh|Millennium Pharmaceuticals, Inc. Adenoid Cystic Carcinoma November 2007 Phase 2
NCT01171092 University of Kansas Medical Center|Millennium Pharmaceuticals, Inc. Malignant Lymphoma, Stem Cell Type|Autologous Transplant September 2010 Early Phase 1
NCT00288028 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm July 2005 Phase 1
NCT00642395 University Hospital, Toulouse|Intergroupe Francophone du Myelome Multiple Myeloma July 2007 Phase 2
NCT00714246 Milton S. Hershey Medical Center|Sanofi Non Small Cell Lung Cancer October 2008 Phase 1|Phase 2
NCT00671112 Brian Hill, MD, PhD|National Cancer Institute (NCI)|The Leukemia and Lymphoma Society|Case Comprehensive Cancer Center 714leukemia|Lymphoma June 2008 Phase 1
NCT03129828 Prof. Dr. Clemens Schmitt|Charite University, Berlin, Germany|Janssen-Cilag Ltd. Diffuse Large B Cell Lymphoma March 17, 2017 Phase 1|Phase 2
NCT00784823 Hackensack University Medical Center Multiple Myeloma January 2007 Phase 1|Phase 2
NCT01842074 Assistance Publique - Hôpitaux de Paris Patients Awaiting a Living Kidney Donation March 2013 Phase 4
NCT01736943 University of California, Davis|Millennium Pharmaceuticals, Inc. Acute Myelogenous Leukemia December 2012 Phase 2
NCT00006773 National Cancer Institute (NCI) Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor May 2001 Phase 1
NCT02893111 Tianjin Medical University General Hospital Neuromyelitis Optica Spectrum Disorder December 2015 Phase 2
NCT01485835 Emory University|Multiple Myeloma Research Consortium|Synta Pharmaceuticals Corp. Multiple Myeloma January 2012 Phase 1
NCT01453088 Hackensack University Medical Center Multiple Myeloma June 2010 Phase 2
NCT00417911 Nordic Myeloma Study Group|Janssen-Cilag Ltd. Multiple Myeloma December 2005 Phase 3
NCT01812096 The First Affiliated Hospital of Soochow University Multiple Myeloma Proved by Laboratory Tests May 2014 Phase 1|Phase 2
NCT01273844 Zhi-Hong Liu, M.D.|Soochow University|Nanjing Medical University|Nanjing University School of Medicine Amyloidosis March 1, 2011
NCT00765102 Celgene Corporation Multiple Myeloma September 2008 Phase 2
NCT02220608 Washington University School of Medicine|Millennium Pharmaceuticals, Inc. Multiple Myeloma February 20, 2015 Phase 1
NCT00903968 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Genzyme, a Sanofi Company|Millennium Pharmaceuticals, Inc. Multiple Myeloma May 2009 Phase 1|Phase 2
NCT01534260 Hamid Sayar|Millennium Pharmaceuticals, Inc.|Bayer|Merck Sharp & Dohme Corp.|Indiana University Acute Myeloid Leukemia February 10, 2012 Phase 1|Phase 2
NCT01497626 Georgetown University|GlaxoSmithKline|Millennium Pharmaceuticals, Inc. Advanced Solid Tumors September 2011 Phase 1
NCT01058239 Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Millennium Pharmaceuticals, Inc. Post-transplant Lymphoproliferative Disease|Solid Organ Transplant|Stem Cell Transplant (Bone Marrow Transplant)|Epstein Barr Virus Infections November 2011 Phase 2
NCT00040768 National Cancer Institute (NCI) Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer April 2002 Phase 2
NCT00372905 Northwestern University|Robert H. Lurie Cancer Center Lymphoma August 2006 Phase 1|Phase 2
NCT00983346 University of Utah|Millennium Pharmaceuticals, Inc. Cancer|Myeloma|Multiple Myeloma October 2009 Phase 2
NCT00923247 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Medullary Thyroid Carcinoma February 19, 2009 Phase 1|Phase 2
NCT00104871 National Cancer Institute (NCI) Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer December 2004 Phase 2
NCT01696474 Gruppo Italiano Malattie EMatologiche dell'Adulto Refractory Cold Agglutinin Disease December 2012 Phase 2
NCT00580320 Virginia Commonwealth University Melanoma|Soft Tissue Sarcoma|Parathyroid Carcinoma|Small Cell Carcinoma of the Lung|Carcinoid Tumors September 2004 Phase 1
NCT00059631 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.|National Cancer Institute (NCI) Prostate Cancer March 2003 Phase 1
NCT02613598 University of Michigan Cancer Center Hodgkin's Lymphoma|Lymphoma, Non-Hodgkin January 2016 Phase 1
NCT02370693 Northwestern University|National Heart, Lung, and Blood Institute (NHLBI) Interstitial Lung Disease|ILD|Systemic Sclerosis|Scleroderma March 2016 Phase 2
NCT00901147 Singapore General Hospital Peripheral T-cell Lymphoma (Not Otherwise Specified)|Angioimmunoblastic T-cell Lymphoma|Extranodal NK/T-cell Lymphoma Nasal Type|Enteropathy- Type T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)|Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant November 2009 Phase 2
NCT00422799 Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc. Waldenstrom's Macroglobulinemia September 2006 Phase 2
NCT00431769 Janssen-Cilag International NV Multiple Myeloma June 2006 Phase 2
NCT00373906 Medical University of Vienna MALT Lymphoma Phase 2
NCT00777738 Assistance Publique - Hôpitaux de Paris Waldenstrom Macroglobulinemia October 2008 Phase 2
NCT00424840 University of Massachusetts, Worcester|Millennium Pharmaceuticals, Inc.|Genentech, Inc. Lung Cancer June 2006 Phase 1|Phase 2
NCT01504477 Georgetown University|Millennium Pharmaceuticals, Inc. Colorectal Cancer December 2011 Phase 1|Phase 2
NCT00508209 Nordic Myeloma Study Group|Janssen-Cilag Ltd. Multiple Myeloma July 2007 Phase 2
NCT01891968 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Leukemia August 7, 2013 Phase 2
NCT01930253 Children's Hospital Medical Center, Cincinnati Refractory Autoimmune Cytopenia(s) July 2012 Phase 1
NCT02356458 Swiss Group for Clinical Cancer Research Mantle Cell Lymphoma August 2015 Phase 1|Phase 2
NCT01524445 Janssen Pharmaceutica N.V., Belgium Hematological Cancer|Multiple Myeloma March 2011 Phase 4
NCT01046006 Meletios A. Dimopoulos|European Myeloma Network|University of Athens Waldenstrom's Macroglobulinemia March 2007 Phase 2
NCT00504634 M.D. Anderson Cancer Center Multiple Myeloma January 2004 Phase 2
NCT00103272 National Cancer Institute (NCI) Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia Wit April 2005 Phase 1
NCT00538187 National Cancer Institute (NCI) Adult Non-Hodgkin Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma December 2007 Phase 1
NCT00516100 Aptium Oncology Research Network|Millennium Pharmaceuticals, Inc. Non-small Cell Lung Cancer January 2006 Phase 1|Phase 2
NCT01397591 OHSU Knight Cancer Institute|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.|GlaxoSmithKline Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma October 2011 Phase 2
NCT01833143 Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc. Non-Small Cell Lung Cancer April 2013 Phase 2
NCT00428545 M.D. Anderson Cancer Center Advanced Malignancy|Lymphoma|Myeloma|Solid Tumors January 2007 Phase 1
NCT01241708 Hackensack University Medical Center Multiple Myeloma|Auto Stem Cell Transplant April 2010 Phase 3
NCT00990652 Northwestern University|Millennium Pharmaceuticals, Inc. Brain and Central Nervous System Tumors May 2009 Phase 2
NCT00072150 National Cancer Institute (NCI) Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Stage III Bladder Cancer|Stage III Urethral Cancer|Stage IV Bladder Cancer|Stage IV Urethral Cancer|Transitional Cell Carcinoma of the Bladder|Ureter Cancer October 2003 Phase 2
NCT00773838 Merck Sharp & Dohme Corp. Relapsed or Refractory Multiple Myeloma December 2008 Phase 2
NCT01183949 Astex Pharmaceuticals|Multiple Myeloma Research Consortium Multiple Myeloma November 2010 Phase 1|Phase 2
NCT00718640 Janssen-Ortho Inc., Canada Multiple Myeloma October 2007 Phase 2
NCT02351427 Asan Medical Center Kidney Transplantation February 2015 Phase 3
NCT02336386 Beijing Chao Yang Hospital|Peking University People's Hospital Extramedullary Plasmacytoma December 2014 Phase 3
NCT00410423 Thomas Jefferson University|Millennium Pharmaceuticals, Inc. Relapsed Acute Leukemia|Refractory Acute Leukemia January 2006 Phase 1|Phase 2
NCT00920855 Cephalon|Teva Pharmaceutical Industries Multiple Myeloma June 2009 Phase 1|Phase 2
NCT00315757 Human Genome Sciences Inc. Multiple Myeloma May 2006 Phase 2
NCT00483262 Dana-Farber Cancer Institute|Wyeth is now a wholly owned subsidiary of Pfizer|Millennium Pharmaceuticals, Inc. Multiple Myeloma May 2007 Phase 1|Phase 2
NCT00570180 University Health Network, Toronto|Princess Margaret Hospital, Canada|Ortho Biotech, Inc. Multiple Myeloma November 2007 Phase 2
NCT01103778 The Rogosin Institute|Weill Medical College of Cornell University Chronic Kidney Disease|IgA Nephropathy July 2010 Phase 4
NCT00479128 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Solid Tumor|Urethral Cancer September 2006 Phase 1
NCT02201576 Assistance Publique - Hôpitaux de Paris|Fondation Centaure Chronic Antibody-mediated Transplant Rejection February 2015 Phase 2
NCT00773747 Merck Sharp & Dohme Corp. Multiple Myeloma December 2008 Phase 3
NCT02467010 University Medical Center Groningen Multiple Myeloma September 2008 Phase 2
NCT00348985 National Cancer Institute (NCI) Adult Grade III Lymphomatoid Granulomatosis|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cel March 2006 Phase 1
NCT00305734 National Cancer Institute (NCI) Recurrent Nasopharyngeal Cancer|Stage IV Nasopharyngeal Cancer August 2006 Phase 2
NCT01023308 Novartis Pharmaceuticals|Novartis Multiple Myeloma December 2009 Phase 3
NCT00287872 Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI) Multiple Myeloma September 2004 Phase 2
NCT00793650 Emory University|Millennium Pharmaceuticals, Inc. Cancer|Multiple Myeloma May 2005 Phase 1|Phase 2
NCT01005628 Janssen Korea, Ltd., Korea Multiple Myeloma June 2006 Phase 4
NCT00290706 Northwestern University|Eli Lilly and Company|Millennium Pharmaceuticals, Inc. Lymphoma September 2005 Phase 1|Phase 2
NCT00722722 Mayo Clinic|Millennium Pharmaceuticals, Inc. Kidney Transplantation June 2008 Phase 2
NCT00142129 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Millennium Pharmaceuticals, Inc. Waldenstrom's Macroglobulinemia|Lymphoplasmacytic Lymphoma December 2003 Phase 2
NCT01226849 Singapore General Hospital|Janssen-Cilag Ltd. Diffuse Large B-Cell Lymphoma November 2010 Phase 1
NCT00492050 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Waldenstrom's Macroglobulinemia August 2006 Phase 2
NCT00083226 National Cancer Institute (NCI) Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer March 2004 Phase 2
NCT01030302 Janssen Korea, Ltd., Korea Multiple Myeloma November 2008 Phase 4
NCT00972712 Emory University|Millennium Pharmaceuticals, Inc.|Ortho Biotech, Inc. Multiple Myeloma December 2006 Phase 1
NCT00054483 National Cancer Institute (NCI) Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Ly January 2003 Phase 1
NCT00369707 Northwestern University|Robert H. Lurie Cancer Center Non-Hodgkin's Lymphoma August 2006 Phase 2
NCT01873157 Medical University of Vienna|Medical University Innsbruck Late Rejection of Renal Transplant|Antibody-mediated Rejection December 2013 Phase 2
NCT00516191 University of California, San Francisco Multiple Myeloma October 2004 Phase 1|Phase 2
NCT00250926 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Millennium Pharmaceuticals, Inc. Waldenstrom's Macroglobulinemia October 2005 Phase 2
NCT00352742 Attenuon Multiple Myeloma June 2006 Phase 1|Phase 2
NCT00985907 University of California, San Francisco Multiple Myeloma|Patient Participation June 2004 Phase 1|Phase 2
NCT00118144 National Cancer Institute (NCI) Adenocarcinoma of the Lung|Bronchoalveolar Cell Lung Cancer|Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer June 2005 Phase 2
NCT00633594 SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc.|Celgene Mantle Cell Lymphoma June 2008 Phase 1|Phase 2
NCT00059618 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer April 2003 Phase 1
NCT00833560 Janssen-Cilag G.m.b.H Multiple Myeloma March 2006 Phase 2
NCT02976272 University Hospital, Clermont-Ferrand|Laboratoires Takeda Multiple Myeloma|Bortezomib Regimen|Adult September 2016
NCT03016988 Tingbo Liu|Union hospital of Fujian Medical University|Fujian Medical University Mantle Cell Lymphoma January 2017 Phase 2
NCT00891033 University of Arkansas|Novartis Multiple Myeloma April 2009 Phase 1
NCT02497378 Janssen Pharmaceutical K.K. Multiple Myeloma July 10, 2015 Phase 1
NCT00376961 Southwest Oncology Group|National Cancer Institute (NCI) Lymphoma August 2006 Phase 2
NCT01315873 New York University School of Medicine|Cephalon Multiple Myeloma September 2011 Phase 2
NCT00963274 Virginia Commonwealth University|National Cancer Institute (NCI) Leukemia|Lymphoma April 26, 2010 Phase 1
NCT02811978 Janssen Research & Development, LLC Multiple Myeloma September 27, 2016 Phase 3
NCT01495351 Alberta Health Services|Tom Baker Cancer Centre|Abbott|AHS Cancer Control Alberta Multiple Myeloma January 2012 Phase 1
NCT01168804 Austrian Forum Against Cancer Multiple Myeloma June 2010 Phase 2
NCT01111188 Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.|Pfizer Mantle Cell Lymphoma June 2010 Phase 1
NCT01164709 Swiss Group for Clinical Cancer Research Leukemia|Lymphoma|Mature T-cell and Nk-cell Neoplasms|Multiple Myeloma and Plasma Cell Neoplasm July 2010 Phase 1
NCT02211755 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neoplasms|Myelodysplastic Syndromes July 30, 2014 Phase 1
NCT00752518 Janssen Pharmaceutical K.K. Refractory|Multiple Myeloma|Relapse May 2004 Phase 1|Phase 2
NCT00425503 Baylor College of Medicine|Millennium Pharmaceuticals, Inc. Prostate Neoplasms December 2001 Phase 2
NCT02139397 Giselle Sholler|Beat NB Cancer Foundation|Because of Ezra|Spectrum Health Hospitals Neuroblastoma Recurrent May 2014 Phase 1|Phase 2
NCT00798720 University of Wisconsin, Madison|Millennium Pharmaceuticals, Inc.|Merck Sharp & Dohme Corp. Carcinoma, Non Small Cell Lung December 2008 Phase 2
NCT01462773 Ohio State University Comprehensive Cancer Center Melanoma January 2006 Phase 1
NCT00536575 SCRI Development Innovations, LLC|Bayer Multiple Myeloma November 2007 Phase 1|Phase 2
NCT00426855 Peter Moosmann|Kantonsspital Aarau Lymphoma, Non-Hodgkin January 2007 Phase 1|Phase 2
NCT02188537 Swiss Group for Clinical Cancer Research Myeloma December 2014 Phase 2
NCT00310024 National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma November 2005 Phase 1
NCT00810576 M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp. Lymphoma January 2009 Phase 2
NCT00075881 National Cancer Institute (NCI) Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma January 2004 Phase 2
NCT02237261 University Hospital Heidelberg|German Cancer Research Center|Janssen-Cilag International NV|Mundipharma Research GmbH & Co KG|inVentiv Health Clinical Multiple Myeloma November 2014 Phase 2
NCT01323920 Dana-Farber Cancer Institute Leukemia|Lymphoma|Myelodysplastic Syndrome May 2011 Phase 2
NCT00093769 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Lymphoma August 2004 Phase 2
NCT00611325 Duke University|Millennium Pharmaceuticals, Inc.|Genentech, Inc. Glioblastoma|Gliosarcoma May 2008 Phase 2
NCT01926899 Indiana University Hematopoetic Stem Cell Transplant August 2013 Phase 1
NCT00077441 National Cancer Institute (NCI) Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer April 2005 Phase 2
NCT01860170 Spectrum Health Hospitals|Millennium Pharmaceuticals, Inc. Hematological Malignancy April 2012 Phase 1|Phase 2
NCT02037256 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Co July 2011
NCT00416208 Janssen-Cilag G.m.b.H Multiple Myeloma October 2006 Phase 3
NCT00608907 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Multiple Myeloma|Non-Hodgkin's Lymphoma September 2007 Phase 1
NCT03110562 Karyopharm Therapeutics Inc Multiple Myeloma June 7, 2017 Phase 3
NCT01680796 University of Florida|Novartis Pharmaceuticals Multiple Myeloma February 2013 Phase 1
NCT01062230 University of Arkansas|Millennium Pharmaceuticals, Inc. Multiple Myeloma January 2010 Phase 2
NCT01465386 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Promyelocytic Leukemia (M3)|Adult Ery November 2011 Phase 2
NCT01119794 Brown University|Rhode Island Hospital|The Miriam Hospital|Memorial Hospital of Rhode Island|Dartmouth-Hitchcock Medical Center Lymphoma, Non-Hodgkins July 2010 Phase 2
NCT01029730 SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc.|Cephalon Lymphoma March 2010 Phase 2
NCT02220049 Gustave Roussy, Cancer Campus, Grand Paris Advanced or Metastatic Solid Tumors December 2010 Phase 1
NCT00937495 National Cancer Institute (NCI) Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma June 2009 Phase 2
NCT02353572 University of Colorado, Denver Plasma Cell Myeloma|Plasmacytosis|Recurrent Plasma Cell Myeloma|Smoldering Plasma Cell Myeloma November 2009 Phase 1|Phase 2
NCT01125293 Dana-Farber Cancer Institute|Novartis|Millennium Pharmaceuticals, Inc. Waldenstrom's Macroglobulinemia March 2010 Phase 1|Phase 2
NCT00580242 Massachusetts General Hospital|Celgene Corporation|Dana-Farber Cancer Institute Myelodysplasia November 2007 Phase 1
NCT00334438 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) Lymphoma July 2006 Phase 1
NCT00401011 Keryx / AOI Pharmaceuticals, Inc. Multiple Myeloma|Multiple Myeloma in Relapse August 2006 Phase 1|Phase 2
NCT00734149 Duke University Multiple Myeloma July 2004 Phase 2
NCT00111813 Merck Sharp & Dohme Corp. Multiple Myeloma September 2005 Phase 1
NCT00777114 Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.|GlaxoSmithKline Non-Hodgkin's Lymphoma October 2008 Phase 1
NCT00895687 M.D. Anderson Cancer Center Advanced Cancer April 2009 Phase 1
NCT01536067 Roswell Park Cancer Institute|National Cancer Institute (NCI)|GlaxoSmithKline Waldenström Macroglobulinemia April 2012 Phase 2
NCT02703779 University of Kansas Medical Center Multiple Myeloma March 2016 Phase 2
NCT01497275 Duke University|Spectrum Pharmaceuticals, Inc Mantle-Cell Lymphoma February 2012 Phase 2
NCT01034553 Mayo Clinic Refractory Multiple Myeloma February 2010 Phase 1|Phase 2
NCT00023712 National Cancer Institute (NCI) Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer July 2004 Phase 2
NCT00720148 Emory University|Millennium Pharmaceuticals, Inc.|Pfizer Solid Tumors February 2008 Phase 1
NCT02902965 Pharmacyclics LLC.|Janssen Research & Development, LLC Multiple Myeloma September 2016 Phase 2
NCT01129180 Pierluigi Porcu|Millennium Pharmaceuticals, Inc.|Celgene Corporation|Ohio State University Comprehensive Cancer Center Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Prolymphocytic Leukemia|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Small Intestine Lymphoma|T-cell Large Granular Lymphocyte Leukemia May 2010 Phase 1
NCT02136134 Janssen Research & Development, LLC Multiple Myeloma August 15, 2014 Phase 3
NCT00560352 Bristol-Myers Squibb Multiple Myeloma February 2008 Phase 1
NCT00276614 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Kidney Cancer April 2006 Phase 2
NCT00093028 University of Arkansas Multiple Myeloma January 2004 Phase 3
NCT01016730 National Cancer Institute (NCI) AIDS-Related Kaposi Sarcoma|HIV Infection|Recurrent Kaposi Sarcoma January 22, 2010 Phase 1
NCT01428492 Novartis Multiple Myeloma December 2011 Phase 1
NCT01255527 Yonsei University Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation October 2010 Phase 1|Phase 2
NCT01734928 Celgene Multiple Myeloma January 7, 2013 Phase 3
NCT00920556 Sirtris, a GSK Company|GlaxoSmithKline Multiple Myeloma March 2009 Phase 2
NCT02840539 Seoul National University Hospital|Consortium for Improving Survival of Lymphoma Mantle Cell Lymphoma October 2016 Phase 2
NCT00770731 M.D. Anderson Cancer Center Advanced Cancer September 2008 Phase 1
NCT03136146 M.D. Anderson Cancer Center Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma September 2017 Phase 2
NCT01322776 Sun Yat-sen University|Fudan University|Zhejiang University|West China Hospital|Ruijin Hospital|Tianjin Medical University Cancer Institute and Hospital|Beijing Cancer Hospital|Jiangsu Cancer Institute & Hospital Mantle Cell Lymphoma Recurrent March 2011 Phase 1|Phase 2
NCT01009840 Otsuka Pharmaceutical Development & Commercialization, Inc. Multiple Myeloma May 2010 Phase 2
NCT01568866 Amgen Multiple Myeloma June 2012 Phase 3
NCT01038388 Emory University|Merck Sharp & Dohme Corp.|Celgene Corporation Multiple Myeloma January 15, 2010 Phase 1
NCT01492881 UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp. Multiple Myeloma April 2012 Phase 2
NCT01497093 Celgene|Multiple Myeloma Research Consortium Multiple Myeloma February 15, 2012 Phase 1
NCT00023764 National Cancer Institute (NCI) Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma June 2001 Phase 2
NCT02658396 Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Phase 1
NCT01286077 Janssen-Cilag International NV Multiple Myeloma September 2009 Phase 2
NCT00664898 Genentech, Inc.|Seattle Genetics, Inc. Multiple Myeloma May 2008 Phase 1
NCT01711528 National Cancer Institute (NCI) Recurrent Plasma Cell Myeloma December 19, 2012 Phase 1
NCT02100657 PharmaMar Multiple Myeloma June 2014 Phase 1
NCT00030368 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific November 2001 Phase 1
NCT00439556 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Lymphoma February 2007 Phase 2
NCT02224729 Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma August 2014 Phase 2
NCT00791011 Amgen Hodgkin's Lymphoma|Low Grade Lymphoma|Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Diffuse Large Cell Lymphoma February 2008 Phase 1
NCT01021592 Janssen Korea, Ltd., Korea Multiple Myeloma March 2007 Phase 4
NCT00310037 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc. Mantle Cell Lymphoma June 2006 Phase 2
NCT01861314 National Cancer Institute (NCI) Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia July 3, 2013 Phase 1
NCT00837174 The Methodist Hospital System Non-Hodgkin Lymphoma June 2010 Phase 2
NCT00005064 National Cancer Institute (NCI) Adult Acute Promyelocytic Leukemia (M3)|Blastic Phase Chronic Myelogenous Leukemia|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia February 2000 Phase 1
NCT00651781 PETHEMA Foundation Acute Myeloid Leukemia April 2008 Phase 1|Phase 2
NCT00479167 Rush University Medical Center|GlaxoSmithKline|Millennium Pharmaceuticals, Inc. Follicular Lymphoma May 2007 Phase 2
NCT02773550 Basque Health Service Multiple Myeloma January 2014 Phase 4
NCT00061932 National Cancer Institute (NCI) Adenocarcinoma of the Gastroesophageal Junction|Diffuse Adenocarcinoma of the Stomach|Intestinal Adenocarcinoma of the Stomach|Mixed Adenocarcinoma of the Stomach|Recurrent Gastric Cancer|Stage IIIB Gastric Cancer|Stage IIIC Gastric Cancer|Stage IV Gastric Cancer April 2003 Phase 2
NCT01530594 King Faisal Specialist Hospital & Research Center Multiple Myeloma January 2009 Phase 3
NCT00182637 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Lymphoma July 2004 Phase 2
NCT02197221 University Hospital, Toulouse|Ministry of Health, France|Janssen, LP Multiple Myeloma January 2015 Phase 3
NCT00416273 Janssen-Cilag G.m.b.H Multiple Myeloma December 2006 Phase 3
NCT00440765 Janssen-Cilag B.V. Multiple Myeloma|Hematological Neoplasms November 2004 Phase 4
NCT01695941 National Cancer Institute (NCI) Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Mantle Cell Lymphoma August 31, 2012 Phase 1
NCT01083602 Novartis Pharmaceuticals|Novartis Relapsed and Bortezomib Refractory Multiple Myeloma|Refractory Multiple Myeloma|Multiple Myeloma in Relapse June 2010 Phase 4
NCT00136591 Lymphoma Study Association|Janssen-Cilag International NV Follicular Lymphoma September 2005 Phase 2
NCT00271804 Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center Myelodysplastic Syndrome June 2005 Phase 1
NCT00818649 Masonic Cancer Center, University of Minnesota|Merck Sharp & Dohme Corp.|Millennium Pharmaceuticals, Inc. Leukemia|Myelodysplastic Syndrome January 2009 Phase 2
NCT00670423 Jennifer E. Schwartz|Millennium Pharmaceuticals, Inc.|Indiana University Graft vs Host Disease|Peripheral Blood Stem Cell Transplantation|Transplantation, Homologous May 2008 Phase 1
NCT02977494 University Hospital Tuebingen Multiple Myeloma December 2016 Phase 2
NCT02797041 IRCCS Centro di Riferimento Oncologico della Basilicata Multiple Myeloma August 2015
NCT01818752 Amgen Multiple Myeloma March 2013 Phase 3
NCT00742625 National Cancer Institute (NCI) Acute Myeloid Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leu September 2008 Phase 1|Phase 2
NCT00439361 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Hodgkin Lymphoma|Lymphoma February 2007 Phase 1
NCT00383474 National Cancer Institute (NCI) Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With August 2006 Phase 1
NCT00477412 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Mantle Cell Lymphoma|Lymphoma April 2007 Phase 1
NCT01440582 M.D. Anderson Cancer Center|Novartis Myeloma February 18, 2013 Phase 1
NCT01026701 Janssen Korea, Ltd., Korea Multiple Myeloma March 2008 Phase 4
NCT01075425 Virginia Commonwealth University|National Cancer Institute (NCI) Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia May 2010 Phase 1
NCT00440479 Janssen-Cilag B.V. Multiple Myeloma|Hematological Neoplasms September 2006 Phase 4
NCT01830465 Gruppo Italiano Studio Linfomi Non Hodgkin's Follicular Lymphoma August 2006 Phase 2
NCT01383759 Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc. Light Chain Deposition Disease (LCDD or MIDD)|Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)|Monoclonal Immunoglobulin Deposition Disease (MIDD)|Amyloidosis June 24, 2011
NCT00869323 Masonic Cancer Center, University of Minnesota|Millennium Pharmaceuticals, Inc. Lymphoproliferative Disorder March 2009 Phase 2
NCT00103506 Janssen Research & Development, LLC Multiple Myeloma December 2004 Phase 3
NCT02808091 National Cancer Centre, Singapore Extranodal NK-T-CELL LYMPHOMA March 2011 Phase 2
NCT00077428 National Cancer Institute (NCI)|Southwest Oncology Group Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Salivary Gland Adenoid Cystic Carcinoma|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Salivary Gland Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Salivary Gland Cancer June 2004 Phase 2
NCT01242267 Hackensack University Medical Center|Millennium Pharmaceuticals, Inc. Multiple Myeloma April 2010 Phase 1|Phase 2
NCT03130348 Mayo Clinic|National Cancer Institute (NCI) Amyloidosis|Immunoglobulin Light Chain Deposition July 15, 2017 Phase 2
NCT00021216 National Cancer Institute (NCI) Unspecified Childhood Solid Tumor, Protocol Specific November 2001 Phase 1
NCT00151320 Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc. Non-Hodgkin's Lymphoma January 2004 Phase 1|Phase 2
NCT01063179 Fondazione Neoplasie Sangue Onlus Multiple Myeloma May 2006 Phase 3
NCT01633645 University Hospital of Crete Non Small Cell Lung Cancer|Metastatic June 2009 Phase 2
NCT02027220 Second Affiliated Hospital of Soochow University Myeloma|Bortezomib|Cyclophosphamide|Dexamethasone|Granulocyte Colony-Stimulating Factor December 2013 Phase 2
NCT00972959 University of Athens Multiple Myeloma July 2009 Phase 2
NCT00703664 National Cancer Institute (NCI) Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma July 9, 2008 Phase 2
NCT01594242 Abramson Cancer Center of the University of Pennsylvania Multiple Myeloma April 2012 Early Phase 1
NCT00025584 National Cancer Institute (NCI) Recurrent Breast Cancer|Stage IV Breast Cancer August 2001 Phase 2
NCT00227513 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific July 2005 Phase 1
NCT00992446 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Adult Diffuse Large B-Cell Lymphoma|B-Cell Non-Hodgkin Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Non-Hodgkin Lymphoma September 2, 2010 Phase 2
NCT00066625 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific July 2003 Phase 1
NCT01329289 University of Pittsburgh|Novartis Multiple Myeloma in Relapse|Multiple Myeloma December 2011 Phase 2
NCT01965353 Dana-Farber Cancer Institute|Novartis Multiple Myeloma in Relapse October 2013 Phase 1
NCT02026505 Oregon Health and Science University|Millennium: The Takeda Oncology Company Multiple Myeloma|Heart Failure, Systolic|Cardiotoxins March 2014
NCT00553644 National Cancer Institute (NCI) Recurrent Mantle Cell Lymphoma November 2007 Phase 2
NCT00998010 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Brain and Central Nervous System Tumors June 2011 Phase 2
NCT01212952 Mayo Clinic|National Cancer Institute (NCI) Refractory Multiple Myeloma September 2011 Phase 1|Phase 2
NCT00369226 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Millennium Pharmaceuticals, Inc. Hematologic Malignancies August 2006 Phase 1|Phase 2
NCT00473590 Genentech, Inc. Multiple Myeloma June 2007 Phase 2
NCT00401843 Janssen Research & Development, LLC Multiple Myeloma November 28, 2006 Phase 2
NCT00515138 University of California, San Francisco Lymphoma, B-Cell May 2007 Early Phase 1
NCT00262873 University of Rochester Myelodysplastic Syndromes May 2005 Phase 2
NCT00307086 H. Lee Moffitt Cancer Center and Research Institute|Millennium Pharmaceuticals, Inc. Multiple Myeloma|Plasma Cell Leukemia June 2005 Phase 2
NCT00088855 National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma June 15, 2004 Phase 2
NCT00861250 Tampere University Hospital|Turku University Hospital|Oulu University Hospital|Kuopio University Hospital|Helsinki University Central Hospital|Central Hospital of Kanta-Hame|Seinajoki Central Hospital|Jyväskylä Central Hospital|Janssen-Cilag Ltd.|Päijänne Tavastia Central Hospital Multiple Myeloma March 2009 Phase 2|Phase 3
NCT00980395 University of Arizona|National Cancer Institute (NCI) Lymphoma|Mantle Cell Lymphoma|Indolent Lymphoma|SLL July 2009 Phase 2
NCT00958256 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Mantle Cell Lymphoma|Lymphoma August 2009 Phase 2
NCT00994500 National Cancer Institute (NCI) Childhood Burkitt Lymphoma|Childhood Central Nervous System Choriocarcinoma|Childhood Central Nervous System Germ Cell Tumor|Childhood Central Nervous System Germinoma|Childhood Central Nervous System Mixed Germ Cell Tumor|Childhood Central Nervous System Teratoma|Childhood Central Nervous System Yolk Sac Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Medulloepithelioma|Childhood Meningi August 2009 Phase 1
NCT00790647 Boston Medical Center Multiple Myeloma June 2008 Phase 2
NCT01267812 City of Hope Medical Center|National Cancer Institute (NCI) Contiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Stage I Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma August 26, 2011 Phase 2
NCT00548717 Dana-Farber Cancer Institute|Wyeth is now a wholly owned subsidiary of Pfizer|PDL BioPharma, Inc. Graft-vs-Host Disease October 2007 Phase 2
NCT00379574 Asan Medical Center|Janssen Korea, Ltd., Korea Lymphoma, Large-Cell, Diffuse|Lymphoma, B-Cell September 2006 Phase 1|Phase 2
NCT01132911 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Lymphoma|Sarcoma|WilmsTumor|Neuroblastoma May 10, 2010 Phase 1
NCT02290431 Novartis Pharmaceuticals|Novartis Relapse/Refractory Multiple Myeloma December 18, 2014 Phase 2
NCT00024011 National Cancer Institute (NCI) Recurrent Melanoma|Stage IV Melanoma July 2001 Phase 2
NCT00077467 National Cancer Institute (NCI) Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Promyelocytic Leukemia (M3)|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia January 2004 Phase 1
NCT02877082 Emory University Acute Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Graft Versus Host Disease|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Neoplasm|Small Lymphocytic Lymphoma September 2016 Phase 2
NCT02441686 Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.|Celgene Multiple Myeloma December 2015 Phase 2
NCT01063907 Kyowa Hakko Kirin Pharma, Inc.|Kyowa Hakko Kirin Co., Ltd|Kyowa Kirin Pharmaceutical Development, Inc. Multiple Myeloma March 2010 Phase 1|Phase 2
NCT01435395 Emory University|Schering-Plough|Genentech, Inc.|Millennium Pharmaceuticals, Inc. Glioblastoma Multiforme December 2011 Phase 1
NCT00652041 PETHEMA Foundation Multiple Myeloma January 2007 Phase 4
NCT01381692 National Cancer Institute (NCI) Cognitive Side Effects of Cancer Therapy|Fatigue|Neurotoxicity Syndrome|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Therapy-Related Toxicity|Waldenstrom Macroglobulinemia July 20, 2011 Phase 1|Phase 2
NCT00091117 National Cancer Institute (NCI) Hepatic Complications|Malignant Neoplasm July 2004 Phase 1
NCT00103259 National Cancer Institute (NCI) Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squam July 2005 Phase 2
NCT00084747 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm June 2004 Phase 1|Phase 2
NCT00703300 National Cancer Institute (NCI) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia June 2008 Phase 1
NCT01056601 Masonic Cancer Center, University of Minnesota|Novartis Pharmaceuticals|Millennium Pharmaceuticals, Inc. Pancreatic Cancer September 2010 Phase 2
NCT00440635 Janssen-Cilag International NV Multiple Myeloma January 2004
NCT01056276 SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc.|Cephalon Multiple Myeloma May 2010 Phase 2
NCT00544284 City of Hope Medical Center|National Cancer Institute (NCI) Brain and Central Nervous System Tumors|Lymphoma|Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific January 2005 Phase 1
NCT00303797 National Cancer Institute (NCI) Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Stage III Multiple Myeloma|Stage IV Chronic Lymphocytic Leukemia|Unspecified Adult Solid Tumor, Protocol Specific December 2005 Phase 1
NCT01913730 Stichting Hemato-Oncologie voor Volwassenen Nederland|Fondazione Neoplasie Sangue Onlus Multiple Myeloma November 2013 Phase 2
NCT00513877 Cancer Trials Ireland Malignant Mesothelioma May 2006 Phase 2
NCT01002248 AEterna Zentaris|Dana-Farber Cancer Institute Multiple Myeloma December 2009 Phase 3
NCT01174888 Alison Walker|Novartis|Millennium Pharmaceuticals, Inc.|Ohio State University Comprehensive Cancer Center Acute Myeloid Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following|Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia August 2010 Phase 1
NCT01163357 City of Hope Medical Center|National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma January 28, 2011 Phase 1
NCT02109861 Henrik Gregersen|Aalborg Universitetshospital Multiple Myeloma January 2014 Early Phase 1
NCT00839956 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma February 2009 Phase 2
NCT00719901 National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma July 2008 Phase 1|Phase 2
NCT01074411 National Cancer Institute (NCI) Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovar April 5, 2010 Phase 1
NCT01083316 Boston Medical Center|Millennium Pharmaceuticals, Inc. Amyloidosis September 2009 Phase 2
NCT00602511 Nordic Myeloma Study Group Multiple Myeloma October 2007 Phase 3
NCT00624936 Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms April 2008 Phase 1
NCT00311337 University of Wuerzburg Multiple Myeloma October 2005 Phase 2
NCT00813150 Janssen-Cilag G.m.b.H Multiple Myeloma January 2009 Phase 3
NCT00075751 National Cancer Institute (NCI) Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer January 2004 Phase 2
NCT00258245 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm May 2005 Phase 1
NCT00082966 National Cancer Institute (NCI) Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma March 2004 Phase 2
NCT01445405 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer February 5, 2008 Phase 1
NCT00510887 Duke University|Millennium Pharmaceuticals, Inc. Lymphoma, Follicular January 2007 Phase 2
NCT00996385 Columbia University Mesothelioma September 2009 Phase 2
NCT00288041 National Cancer Institute (NCI) Ciliary Body and Choroid Melanoma, Medium/Large Size|Extraocular Extension Melanoma|Iris Melanoma|Recurrent Intraocular Melanoma|Recurrent Melanoma|Stage IV Melanoma October 2005 Phase 2
NCT00641706 National Cancer Institute (NCI) Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor July 2008 Phase 2
NCT01127009 Case Comprehensive Cancer Center Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adul July 2010 Phase 1
NCT00124579 Southwest Oncology Group|National Cancer Institute (NCI) Multiple Myeloma August 2005 Phase 2
NCT00335348 Peter MacCallum Cancer Centre, Australia|Janssen-Cilag Ltd. Multiple Myeloma June 2006 Phase 2
NCT00262860 University of Rochester Lymphoma April 2005 Phase 2
NCT00068315 National Cancer Institute (NCI) Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hematopoietic/Lymphoid Cancer|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia July 2003 Phase 1
NCT00636311 Istituto Clinico Humanitas Hodgkin Disease February 2008 Phase 2
NCT01728259 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Light Chain Deposition Disease|Primary Systemic Amyloidosis March 2013 Phase 1
NCT00096005 National Cancer Institute (NCI) Adult Grade III Lymphomatoid Granulomatosis|AIDS-related Peripheral/Systemic Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurre November 2004 Phase 1
NCT00520767 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Primary Systemic Amyloidosis|Light Chain Deposition Disease September 2007 Phase 2
NCT00547534 University of Rochester|Millennium Pharmaceuticals, Inc.|Cephalon Non-Hodgkin's Lymphoma October 2007 Phase 2
NCT00590603 Duke University|Cephalon Multiple Myeloma July 2008 Phase 1
NCT01950611 Christian Medical College, Vellore, India Relapsed Acute Promyelocytic Leukemia May 2013 Phase 2
NCT00085410 National Cancer Institute (NCI) Adenocarcinoma of the Extrahepatic Bile Duct|Adenocarcinoma of the Gallbladder|Advanced Adult Primary Liver Cancer|Gastrointestinal Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer January 2004 Phase 2
NCT02112916 National Cancer Institute (NCI) Adult T Acute Lymphoblastic Leukemia|Childhood T Acute Lymphoblastic Leukemia|Stage II Childhood Lymphoblastic Lymphoma|Stage II Contiguous Adult Lymphoblastic Lymphoma|Stage II Non-Contiguous Adult Lymphoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia September 30, 2014 Phase 3
NCT00667641 University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Melanoma (Skin)|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific March 2007 Phase 1
NCT01998503 Nanjing University School of Medicine Amyloidosis December 2007 Phase 3
NCT00064012 University of Wisconsin, Madison|National Cancer Institute (NCI) Lung Cancer May 2003 Phase 2
NCT00832234 European Myeloma Network|University of Athens|University of Roma La Sapienza|Niguarda Hospital|University of Turin, Italy|University of Salamanca|Hospital Clinic of Barcelona|Hotel Dieu Hospital|Erasmus Medical Center|University Hospital, Toulouse|IRCCS Policlinico S. Matteo|Laikon General District Hospital, Athens|Klinikum der Universitaet Muenchen, Grosshadern|Aalborg Universitetshospital|Centre Hospitalier de Lens|Universitaire Ziekenhuizen Leuven|Theagenio Cancer Hospital|University of Wuerzburg|Skane University Hospital|Sahlgren´s University Hospital Waldenstroms Macroglobulinemia September 2006 Phase 2
NCT00724568 University of Michigan Cancer Center Multiple Myeloma May 2008 Phase 1|Phase 2
NCT00052338 National Cancer Institute (NCI) Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer September 2002 Phase 1
NCT03117361 PharmaMar Multiple Myeloma November 15, 2016 Phase 2
NCT00108069 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Glioma April 2005 Phase 2
NCT01142401 National Cancer Institute (NCI) Estrogen Receptor Positive|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer May 26, 2010 Phase 2
NCT00243035 National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma August 2005 Phase 1|Phase 2
NCT00863369 City of Hope Medical Center|National Cancer Institute (NCI) Lymphoma June 20, 2005 Phase 1|Phase 2
NCT02371148 Fondazione Italiana Linfomi ONLUS Waldenstrom's Macroglobulinemia June 2014 Phase 2
NCT00038571 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Lymphoma, B-Cell May 2002 Phase 2
NCT02844322 Institute of Hematology & Blood Diseases Hospital Waldenström Macroglobulinemia May 2016 Phase 4
NCT00045695 NCIC Clinical Trials Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group Lymphoma August 2002 Phase 2
NCT01919086 Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc.|Hartford Hospital Multiple Myeloma (MM) August 2013 Phase 2
NCT02082405 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma April 2015 Phase 2
NCT00510939 University of Bologna|Janssen-Cilag Ltd. Acute Myeloid Leukemia March 2007 Phase 2
NCT00411905 Groupe Francophone des Myelodysplasies Myelodysplastic Syndromes June 2006 Phase 1|Phase 2
NCT00028587 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific December 2001 Phase 1
NCT00411593 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.|Genentech, Inc. Lung Cancer November 2006 Phase 1|Phase 2
NCT02375555 Dana-Farber Cancer Institute|Bristol-Myers Squibb Multiple Myeloma May 2015 Phase 2
NCT00431990 Peter MacCallum Cancer Centre, Australia|Celgene Corporation|Janssen-Cilag Ltd. Multiple Myeloma November 2006 Phase 1|Phase 2
NCT01206205 University Hospital, Toulouse|Celgene Corporation|Janssen-Cilag Ltd. Multiple Myeloma August 2009 Phase 2
NCT01439750 Milton S. Hershey Medical Center Mantle Cell Lymphoma May 2012 Phase 1|Phase 2
NCT01531998 M.D. Anderson Cancer Center|Janssen Services, LLC Myeloma May 2012 Phase 1|Phase 2
NCT02489500 Boston Medical Center AL Amyloidosis June 2015 Phase 3
NCT00629226 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Head and Neck Cancer October 2007 Phase 1
NCT02718833 Massachusetts General Hospital|Celgene|Bristol-Myers Squibb|Multiple Myeloma Research Consortium Multiple Myeloma June 2016 Phase 2
NCT01504776 Anand Jillella|Novartis Pharmaceuticals|Augusta University Mantle Cell Lymphoma April 2011 Phase 1
NCT01078961 Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Bayer|Millennium Pharmaceuticals, Inc. Melanoma September 2010 Phase 1
NCT00511069 University of Bologna Leukemia July 2006 Phase 2
NCT00407303 Gemin X|Teva Pharmaceutical Industries Mantle-Cell Lymphoma October 2006 Phase 1|Phase 2
NCT00744354 UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp.|Millennium Pharmaceuticals, Inc.|Ortho Biotech, Inc. Multiple Myeloma and Plasma Cell Neoplasm October 2008 Phase 1
NCT01349595 Mark Stegall|Millennium Pharmaceuticals, Inc.|Mayo Clinic Disorder of Transplanted Kidney December 2011 Phase 2
NCT01078454 National Cancer Institute (NCI) Light Chain Deposition Disease|Primary Systemic Amyloidosis November 2010 Phase 3
NCT01300793 University of California, San Francisco|Millennium Pharmaceuticals, Inc. Non-Hodgkin's Lymphoma|B-cell Lymphoma May 2007 Phase 1
NCT00378105 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc. Multiple Myeloma September 2006 Phase 1|Phase 2
NCT00080405 Millennium Pharmaceuticals, Inc. Multiple Myeloma March 2004 Phase 1
NCT02874742 Janssen Research & Development, LLC Multiple Myeloma August 29, 2016 Phase 2
NCT00378209 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc. Multiple Myeloma August 2006 Phase 2
NCT00193557 SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc. Multiple Myeloma May 2004 Phase 2
NCT00401804 Austrian Forum Against Cancer Multiple Myeloma|Renal Insuficiency February 2006 Phase 2
NCT00469209 M.D. Anderson Cancer Center|Cephalon Myeloma June 2006 Phase 1|Phase 2
NCT02514382 University of Southern California|National Cancer Institute (NCI)|Oncolytics Biotech Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma August 21, 2015 Phase 1
NCT00107341 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Esophageal Cancer August 2005 Phase 2
NCT01072773 Mayo Clinic Primary Systemic Amyloidosis March 2010 Phase 2
NCT01788020 University of Ulm Waldenström's Macroglobulinemia November 2013 Phase 3
NCT00358020 University of Turin, Italy Multiple Myeloma November 2004 Phase 2
NCT02353468 University of Colorado, Denver Refractory Plasma Cell Myeloma December 2009 Phase 2
NCT01324596 University Hospital Southampton NHS Foundation Trust|Janssen-Cilag Ltd. Lymphoma, Large B-Cell, Diffuse April 2011 Phase 3
NCT02559154 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Multiple Myeloma July 2010 Phase 4
NCT00027898 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific January 2002 Phase 1
NCT00291538 Nantes University Hospital Multiple Myeloma February 2006 Phase 1
NCT00858234 Merck Sharp & Dohme Corp. Multiple Myeloma March 2009 Phase 1
NCT01668719 Southwest Oncology Group|National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma November 2012 Phase 1|Phase 2
NCT00329589 Sidney Kimmel Cancer Center at Thomas Jefferson University|Millennium Pharmaceuticals, Inc.|Thomas Jefferson University Brain Cancer|Head and Neck Cancer|Cervix Cancer|Central Nervous System Neoplasms September 2005 Phase 1
NCT00428142 NCIC Clinical Trials Group|Canadian Cancer Trials Group Lymphoma December 2006 Phase 2
NCT00507416 Millennium Pharmaceuticals, Inc. Multiple Myeloma June 2007 Phase 3
NCT01449344 Prof. Dr. M. Dreyling (co-chairman)|Klinikum der Universitaet Muenchen, Grosshadern|ClinAssess GmbH|GELARC Service de Pharmacovigilance, Pierre Benite|European Mantle Cell Lymphoma Network Mantle Cell Lymphoma May 9, 2009 Phase 3
NCT01208662 Paul G. Richardson, MD|Celgene Corporation|Millennium Pharmaceuticals, Inc.|Massachusetts General Hospital|Cape Cod Healthcare|Beth Israel Deaconess Medical Center|Emory University|University of Michigan|Fox Chase Cancer Center|Memorial Sloan Kettering Cancer Center|Fred Hutchinson Cancer Research Center|Barbara Ann Karmanos Cancer Institute|Duke University|University of California, San Francisco|University of Chicago|M.D. Anderson Cancer Center|UNC Lineberger Comprehensive Cancer Center|Roswell Park Cancer Institute|Stanford University|University of Mississippi Medical Center|Icahn School of Medicine at Mount Sinai|Wake Forest University Health Sciences|University of Arizona|OHSU Knight Cancer Institute|Eastern Maine Medical Center|University of California, San Diego|University of Alabama at Birmingham|University of Pittsburgh|Ochsner Health System|University of Texas Southwestern Medical Center|State University of New York - Downstate Medical Center|Newton-Wellesley Hospital|Baylor College of Medicine|City of Hope Medical Center|University of Florida|Northwell Health|H. Lee Moffitt Cancer Center and Research Institute|Vanderbilt University Medical Center|Ohio State University|Huntsman Cancer Institute|Columbia University|Dana-Farber Cancer Institute Multiple Myeloma September 2010 Phase 3
NCT02755597 AbbVie|Genentech, Inc. Relapsed/Refractory Multiple Myeloma July 11, 2016 Phase 3
NCT00280176 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) Colorectal Cancer April 2003 Phase 1
NCT01769209 Stanford University|National Cancer Institute (NCI) B-cell Adult Acute Lymphoblastic Leukemia|Ph Positive Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia March 2013 Phase 2
NCT00007878 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific September 2000 Phase 1
NCT00416793 National Cancer Institute (NCI) Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Stage IV Pancreatic Cancer December 2006 Phase 2
NCT00522392 National Cancer Institute (NCI) Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma September 2007 Phase 3
NCT00708292 Novartis Pharmaceuticals|Novartis Relapsed or Refractory Multiple Myeloma July 2008 Phase 1|Phase 2
NCT01539083 Janssen Scientific Affairs, LLC Multiple Myeloma January 13, 2012 Phase 3
NCT00082784 National Cancer Institute (NCI) Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Plasma Cell Myeloma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglo March 2004 Phase 1
NCT00531453 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Multiple Myeloma October 2007 Phase 2
NCT00052689 National Cancer Institute (NCI) Duct Cell Adenocarcinoma of the Pancreas|Stage IV Pancreatic Cancer December 2002 Phase 2
NCT03201965 Janssen Research & Development, LLC Amyloidosis September 1, 2017 Phase 3
NCT01453101 Hackensack University Medical Center Multiple Myeloma June 9, 2010 Phase 2
NCT02783625 Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|Stanford University Lymphoma|Relapsed/Refractory T-cell Lymphomas May 2016 Phase 1
NCT01794507 AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie Relapsed/Refractory Multiple Myeloma November 26, 2012 Phase 1
NCT00564200 PETHEMA Foundation Multiple Myeloma November 2007 Phase 2
NCT01863004 University Hospital, Basel, Switzerland Dysferlinopathy December 2012 Phase 1
NCT00362882 National Cancer Institute (NCI) Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer July 2006 Phase 2
NCT00555906 Pfizer Multiple Myeloma January 2008 Phase 2
NCT01936090 Mayo Clinic|National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma August 2013 Phase 1|Phase 2
NCT01537861 Washington University School of Medicine Multiple Myeloma June 2012 Early Phase 1
NCT00030875 NCIC Clinical Trials Group|Canadian Cancer Trials Group Lymphoma July 2002 Phase 2
NCT01706666 Mayo Clinic Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma December 2012 Phase 2
NCT00148018 University of Cologne|German Hodgkin's Lymphoma Study Group|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Hodgkin Disease March 2005 Phase 2
NCT00052507 University Health Network, Toronto|National Cancer Institute (NCI) Colorectal Cancer January 2003 Phase 2
NCT00027716 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Sarcoma October 2001 Phase 2
NCT00967369 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Hodgkin's Lymphoma August 2009 Phase 2
NCT01078441 National Cancer Institute (NCI) Refractory Multiple Myeloma September 2010 Phase 2
NCT00644228 National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma April 2008 Phase 3
NCT00118183 National Cancer Institute (NCI) Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Large Cell Lung Cancer|Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer July 2005 Phase 2
NCT00066508 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Lymphoma May 2003 Phase 2
NCT00458822 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm February 2007 Phase 2
NCT02474563 Janssen Korea, Ltd., Korea Multiple Myeloma May 2011 Phase 4
NCT00068484 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific July 2003 Phase 1
NCT00210392 International Extranodal Lymphoma Study Group (IELSG) Lymphoma, Mucosa-Associated Lymphoid Tissue July 2005 Phase 2
NCT01592981 University College, London Waldenstrom's Macroglobulinaemia January 2013 Phase 2
NCT00066352 University Health Network, Toronto|National Cancer Institute (NCI) Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter September 2003 Phase 2
NCT00093756 National Cancer Institute (NCI) Recurrent Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer September 2004 Phase 1|Phase 2
NCT00666588 National Cancer Institute (NCI) Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Childhood Acute Basophilic Leukemia|Childhood Acute Eosinophilic April 2008 Phase 2
NCT00074009 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Gastric Cancer October 2003 Phase 2
NCT00114738 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Lymphoma, Mantle Cell|Mantle Cell Lymphoma June 15, 2005 Phase 2
NCT00290680 Medical University of South Carolina Unspecified Adult Solid Tumor, Protocol Specific March 2005 Phase 1
NCT00068289 Southwest Oncology Group|National Cancer Institute (NCI) Lung Cancer September 2003 Phase 2
NCT00504101 University of Miami Multiple Myeloma and Plasma Cell Neoplasm June 2007 Phase 1
NCT00513955 Plymouth Hospitals NHS Trust Lymphoma June 2006 Phase 2
NCT01910987 Janssen-Cilag International NV Multiple Myeloma April 2013 Phase 3
NCT00377052 NCIC Clinical Trials Group|Canadian Cancer Trials Group Lymphoma June 2006 Phase 2
NCT00440726 Therapeutic Advances in Childhood Leukemia Consortium Acute Lymphoblastic Leukemia June 2006 Phase 1|Phase 2
NCT00458913 European Organisation for Research and Treatment of Cancer - EORTC Malignant Mesothelioma February 2007 Phase 2
NCT02522572 E. Steve Woodle|Sanofi-Synthelabo|University of Cincinnati Transplants and Implants August 2015 Phase 1|Phase 2
NCT00750815 H. Lee Moffitt Cancer Center and Research Institute|Millennium Pharmaceuticals, Inc.|Ortho Biotech, Inc. Multiple Myeloma September 2008 Phase 1|Phase 2
NCT00388089 University of California, Davis|National Cancer Institute (NCI) Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific December 2004 Phase 1
NCT00028912 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer November 2001 Phase 1
NCT02542111 Ruijin Hospital Diffuse Large B-cell Lymphoma May 2015 Phase 2
NCT00316940 Oncotherapeutics|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm December 2005 Phase 1
NCT00129207 Millennium Pharmaceuticals, Inc. Tumors Phase 1
NCT01286272 National Cancer Institute (NCI) Grade 3a Follicular Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma April 8, 2011 Phase 2
NCT00740415 French Innovative Leukemia Organisation|Janssen, LP|Mundipharma Pte Ltd. Lymphoma June 2007 Phase 2
NCT01191060 University Hospital, Toulouse|Dana-Farber Cancer Institute|Celgene Corporation|Janssen-Cilag Ltd. Myeloma October 2010 Phase 3
NCT00425750 Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) Head and Neck Cancer August 2005 Phase 2
NCT00381940 National Cancer Institute (NCI) Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Childhood Lymphocyte Depletion Hodgkin Lymphoma|Childhood Lymphocyte Predominant Hodgkin Lymphoma|Childhood Mixed Cellularity Hodgkin Lymphoma|Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Childhood Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymp January 2007 Phase 2
NCT00257114 Millennium Pharmaceuticals, Inc. Multiple Myeloma Phase 4
NCT01332617 James Graham Brown Cancer Center Myeloma April 2011 Phase 2
NCT01605032 Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma February 2012 Phase 2
NCT00541359 City of Hope Medical Center Unspecified Adult Solid Tumor, Protocol Specific January 2004 Phase 1
NCT00799539 Janssen-Ortho Inc., Canada|Ortho Biotech Canada Multiple Myeloma
NCT00023881 M.D. Anderson Cancer Center|National Cancer Institute (NCI) Leukemia July 2001 Phase 2
NCT01522872 Threshold Pharmaceuticals Multiple Myeloma February 2012 Phase 1|Phase 2
NCT00884546 Bristol-Myers Squibb|Exelixis Advanced Cancer, Various, NOS July 2009 Phase 1
NCT00571493 University of Nebraska|Millennium Pharmaceuticals, Inc. Non-hodgkin's Lymphoma|Mantle Cell Lymphoma April 2006 Phase 1|Phase 2
NCT02513186 Sanofi Plasma Cell Myeloma September 30, 2015 Phase 1
NCT00366106 Accelerated Community Oncology Research Network|Millennium Pharmaceuticals, Inc. Multiple Myeloma July 2006 Phase 2
NCT01782963 Massachusetts General Hospital Multiple Myeloma March 2013 Phase 2
NCT00216697 Janssen Pharmaceutical K.K. Multiple Myeloma March 2005 Phase 2
NCT00514371 Bristol-Myers Squibb Multiple Myeloma August 2007 Phase 2|Phase 3
NCT00849251 University of Washington|National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma November 2008 Phase 1|Phase 2
NCT01312818 Masonic Cancer Center, University of Minnesota|Millennium Pharmaceuticals, Inc. Acute Lymphoblastic Leukemia June 2011 Phase 2
NCT00706953 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Centocor Ortho Biotech Services, L.L.C. Multiple Myeloma July 2008 Phase 2
NCT01313897 University of Arkansas|National Institutes of Health (NIH) Multiple Myeloma January 2011 Phase 2
NCT01769443 National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation Primary Heart Transplant|Heart Transplantation|Heart Transplant June 2013 Phase 2
NCT00389701 Sparrow Regional Cancer Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm March 2006 Phase 2
NCT00193232 SCRI Development Innovations, LLC|Aventis Pharmaceuticals|Millennium Pharmaceuticals, Inc. Prostate Cancer May 2004 Phase 2
NCT02484261 Reuven Schore|Millennium Pharmaceuticals, Inc.|Hyundai Hope On Wheels|Children's Research Institute Leukemia May 2015 Phase 1
NCT01478048 Bristol-Myers Squibb|AbbVie Multiple Myeloma November 2011 Phase 2
NCT00098982 European Organisation for Research and Treatment of Cancer - EORTC Colorectal Cancer September 2004 Phase 1
NCT00561743 Janssen-Ortho Inc., Canada Multiple Myeloma November 2005 Phase 2
NCT01534143 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma February 2012 Phase 2
NCT00312845 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Non-Hodgkin's Lymphoma March 2006 Phase 3
NCT00458705 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm November 2006 Phase 2
NCT00598169 AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation Lymphoma November 2007 Phase 1
NCT01394354 University Hospital Freiburg|Merck Sharp & Dohme Corp.|Janssen-Cilag Ltd. Multiple Myeloma in Relapse August 2011 Phase 1|Phase 2
NCT01359657 Bristol-Myers Squibb Multiple Myeloma September 2011 Phase 1
NCT00295932 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|Columbia University|Emory University Leukemia|Lymphoma December 2005 Phase 1|Phase 2
NCT00298779 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Tumors|Non-Hodgkins's Lymphoma Phase 1
NCT01177683 Sherif Farag, MB, BS|Hoosier Cancer Research Network|Cephalon Multiple Myeloma July 2010 Phase 1|Phase 2
NCT00441168 Janssen-Cilag International NV Multiple Myeloma December 2006 Phase 2
NCT02605356 Bayer Multiple Myeloma October 2016 Phase 1|Phase 2
NCT02424851 Oxford University Hospitals NHS Trust|Janssen-Cilag Ltd.|Bloodwise|University of Warwick|University of Birmingham Multiple Myeloma|Chronic Kidney Disease November 2014 Phase 2
NCT00523848 Roswell Park Cancer Institute Multiple Myeloma and Plasma Cell Neoplasm June 2006 Phase 2
NCT00361621 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Millennium Pharmaceuticals, Inc. Non-Hodgkin's Lymphoma July 2006 Phase 2
NCT01863550 ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma November 2013 Phase 3
NCT02419755 St. Jude Children's Research Hospital Mixed Lineage Acute Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia April 2015 Phase 2
NCT00317811 Oncotherapeutics|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm November 2005 Phase 2
NCT00006098 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes April 2000 Phase 1
NCT02955810 National University of Ireland, Galway, Ireland|Janssen Pharmaceuticals|Cancer Trials Ireland Multiple Myeloma November 2016 Phase 1
NCT00184015 University of Southern California Renal Cell Cancer August 18, 2005 Phase 1|Phase 2
NCT00948922 H. Lee Moffitt Cancer Center and Research Institute|Millennium Pharmaceuticals, Inc. Multiple Myeloma June 18, 2009 Phase 2
NCT00210327 International Extranodal Lymphoma Study Group (IELSG) Lymphoma, Mucosa-Associated Lymphoid Tissue July 2005 Phase 2
NCT00792142 City of Hope Medical Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm|Neurotoxicity January 2008 Phase 2
NCT01386398 European Organisation for Research and Treatment of Cancer - EORTC Lymphoma Phase 3
NCT01554852 University of Leeds|Celgene|Merck Sharp & Dohme Corp.|Amgen Multiple Myeloma May 2010 Phase 3
NCT00436059 Vejle Hospital|Odense University Hospital Multiple Myeloma February 2007 Phase 2
NCT01754389 Dana-Farber Cancer Institute Graft Versus Host Disease January 2013 Phase 2
NCT00028639 Northwestern University|National Cancer Institute (NCI) Breast Cancer August 2001 Phase 2
NCT00546780 Bristol-Myers Squibb Multiple Myeloma February 2008 Phase 3
NCT00111319 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Multiple Myeloma December 2004 Phase 3
NCT00004002 New York University School of Medicine|National Cancer Institute (NCI) Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific July 1999 Phase 1
NCT00017199 Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) Gastrointestinal Carcinoid Tumor|Islet Cell Tumor April 2001 Phase 2
NCT00017329 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Kidney Cancer April 2001 Phase 2
NCT01248923 Array BioPharma Multiple Myeloma, Plasma Cell Leukemia December 2010 Phase 1
NCT00609167 Mayo Clinic|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm December 2006 Phase 2
NCT01916252 PETHEMA Foundation|Janssen, LP|Celgene|Pierre Fabre Medicament Multiple Myeloma September 2013 Phase 3
NCT00334932 Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm February 2006 Phase 1|Phase 2
NCT00931918 Millennium Pharmaceuticals, Inc.|Takeda Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) October 2009 Phase 2
NCT00256776 European Group for Blood and Marrow Transplantation|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Celgene Corporation Multiple Myeloma July 2005 Phase 3
NCT00389805 University of California, Davis|Eli Lilly and Company Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific March 2005 Phase 1|Phase 2
NCT00711828 Mayo Clinic|National Cancer Institute (NCI) Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia August 2008 Phase 2
NCT01954784 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma October 7, 2013 Phase 1
NCT02654990 Novartis Pharmaceuticals|Novartis Multiple Myeloma April 27, 2016 Phase 2
NCT00063726 Millennium Pharmaceuticals, Inc. Multiple Myeloma April 2002 Phase 3
NCT00006362 Mayo Clinic|National Cancer Institute (NCI) Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific November 1999 Phase 1
NCT01216683 Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Lymphoma December 2010 Phase 2
NCT00103103 California Cancer Consortium|National Cancer Institute (NCI) Gastric Cancer March 2005 Phase 2
NCT01647165 National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.|National Institutes of Health Clinical Center (CC) Multiple Myeloma July 11, 2012 Phase 2
NCT00478075 Mayo Clinic|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm September 2005 Phase 1|Phase 2
NCT00568880 University of Pennsylvania|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm November 2007 Phase 1|Phase 2
NCT01685814 Wuerzburg University Hospital|ClinAssess GmbH|Celgene Corporation Previously Untreated Symptomatic Multiple Myeloma May 2012 Phase 3
NCT01848132 Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Janssen-Cilag, S.A. Diffuse, Large B-Cell, Lymphoma October 3, 2013 Phase 2
NCT00063791 Millennium Pharmaceuticals, Inc. Multiple Myeloma
NCT00063713 Millennium Pharmaceuticals, Inc. Mantle Cell Lymphoma June 2003 Phase 2
NCT01371981 National Cancer Institute (NCI) Leukemia Cutis|Myeloid Sarcoma|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Myeloid Neoplasm June 20, 2011 Phase 3
NCT01484626 Loyola University Multiple Myeloma May 2011 Phase 1|Phase 2
NCT00048230 Millennium Pharmaceuticals, Inc. Multiple Myeloma June 2002 Phase 3
NCT02362165 Sun Yat-sen University Multiple Myeloma April 2015 Phase 3
NCT00103376 Medical University of South Carolina Prostate Cancer October 2004 Phase 2
NCT01415752 Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Lymphoma|Neurotoxicity|Therapy-related Toxicity May 2012 Phase 2
NCT00148317 Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc. Multiple Myeloma June 2005 Phase 2
NCT00908232 Janssen-Cilag International NV Multiple Myeloma May 2008 Phase 2
NCT01208766 Stichting Hemato-Oncologie voor Volwassenen Nederland|European Myeloma Network|GIMEMA (Italian Group for Adult Hematologic Diseases)|DSMM (Deutsche Studiengruppe Multiples Myelom)|NMSG (Nordic Myeloma Study Group)|Central European Myeloma Study Group Multiple Myeloma January 2011 Phase 3
NCT00507442 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Multiple Myeloma August 2007 Phase 1|Phase 2
NCT01420926 National Cancer Institute (NCI) Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myelo November 2011 Phase 2
NCT00011778 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Squamous Cell Carcinoma February 22, 2001 Phase 1
NCT00911859 Janssen Research & Development, LLC Multiple Myeloma June 2009 Phase 2
NCT00051974 Millennium Pharmaceuticals, Inc. Non-Small Cell Lung Cancer December 2002 Phase 2
NCT00051987 Millennium Pharmaceuticals, Inc. Colorectal Carcinoma December 2002 Phase 2
NCT00064636 Millennium Pharmaceuticals, Inc. Advanced Non-Small Cell Lung Cancer|Other Solid Tumors December 2002 Phase 1
NCT02219178 Cancer Trials Ireland Multiple Myeloma November 2014 Phase 2
NCT00610792 Millennium Pharmaceuticals, Inc. Ovarian Cancer July 2006 Phase 2
NCT00265928 University of Virginia|National Cancer Institute (NCI) Lymphoma Phase 2
NCT00873093 National Cancer Institute (NCI) B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia March 2009 Phase 2
NCT00793572 Fred Hutchinson Cancer Research Center|Millennium Pharmaceuticals, Inc.|National Cancer Institute (NCI) Refractory Plasma Cell Myeloma October 2008 Phase 2
NCT00742404 Oncotherapeutics|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm July 2008 Phase 2
NCT00772668 University of Miami Lymphoma September 2008
NCT00064610 Millennium Pharmaceuticals, Inc. Prostatic Neoplasms December 2002 Phase 1|Phase 2
NCT00438841 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm August 2006 Phase 2
NCT02541383 Intergroupe Francophone du Myelome|HOVON - Dutch Haemato-Oncology Association|Janssen Research & Development, LLC Multiple Myeloma September 2015 Phase 3
NCT01249690 Second Military Medical University|Zhejiang University|Peking University People's Hospital|Fourth Military Medical University|Xiangya Hospital of Central South University|Institute of Hematology & Blood Diseases Hospital|Union hospital of Fujian Medical University|Harbin Hematology and Oncology Institute|First Affiliated Hospital, Sun Yat-Sen University|Beijing Jishuitan Hospital Multiple Myeloma June 2010 Phase 4
NCT00217503 National Cancer Institute (NCI) Lymphoma July 2005 Phase 2
NCT00023855 University of Wisconsin, Madison|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific June 2001 Phase 1
NCT00106262 Women and Infants Hospital of Rhode Island|Millennium Pharmaceuticals, Inc. Cervical Cancer March 2005 Phase 2
NCT01000285 Washington University School of Medicine Leukemia-Lymphoma, Adult T-Cell September 2010 Phase 1|Phase 2
NCT00095680 Scios, Inc. Multiple Myeloma November 2004 Phase 2
NCT02928029 Bayer Multiple Myeloma February 10, 2017 Phase 1|Phase 2
NCT01548573 University of Iowa|National Cancer Institute (NCI) Multiple Myeloma May 2012 Phase 2
NCT01460420 European Myeloma Network Hematologic Malignancies|Multiple Myeloma November 2011 Phase 1|Phase 2
NCT00851552 Roswell Park Cancer Institute|Ortho Biotech, Inc. Lymphoma January 2009 Phase 2
NCT00313690 University of Southern California Lung Cancer April 2006 Phase 1|Phase 2
NCT02951819 Janssen Scientific Affairs, LLC Multiple Myeloma November 9, 2016 Phase 2
NCT00283634 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NSCLC August 2005 Phase 2
NCT00814541 Cancer Trials Ireland Multiple Myeloma and Plasma Cell Neoplasm December 2005 Phase 2
NCT02481934 Joaquín Martínez López, MD, PhD|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Hospital Universitario 12 de Octubre Multiple Myeloma March 2013 Phase 1
NCT00609817 La Jolla Pharmaceutical Company Multiple Myeloma May 2008 Phase 1
NCT00995059 Mayo Clinic Multiple Myeloma|Refractory Multiple Myeloma Phase 1|Phase 2
NCT01556438 Eli Lilly and Company Multiple Myeloma July 2012 Phase 1
NCT00871546 Merck Sharp & Dohme Corp. Lymphoma, Mantle-Cell|Leukemia, Lymphocytic, Chronic, B-Cell March 2009 Phase 2
NCT01653418 Washington University School of Medicine Multiple Myeloma September 2012 Phase 2
NCT02086942 Yongping Zhai|Jinling Hospital, China Multiple Myeloma August 2013 Phase 2
NCT01481194 Vejle Hospital|The University of Hong Kong Multiple Myeloma November 2011 Phase 2
NCT00634179 Emory University|Millennium Pharmaceuticals, Inc. Lymphoma, B-Cell|Follicular Lymphoma February 2008 Phase 1|Phase 2
NCT03000634 University of Arkansas Multiple Myeloma May 2017 Phase 2
NCT02518750 St. Jude Children's Research Hospital|Novartis Pharmaceuticals|Spectrum Pharmaceuticals, Inc Acute Lymphoblastic Leukemia|Lymphoma, Non-Hodgkin's|Leukemia, T-Cell|Leukemia, B-Cell November 23, 2016 Phase 2
NCT01602224 Eli Lilly and Company Multiple Myeloma July 2012 Phase 2
NCT01250808 Peking University Multiple Myeloma
NCT00723658 Southwest Oncology Group|National Cancer Institute (NCI) Lymphoma September 2008 Phase 2
NCT00261612 Medical University of Vienna Lymphoma, Mantle-Cell January 2005 Phase 2
NCT02352558 Boston Biomedical, Inc Hematologic Malignancy May 2015 Phase 1
NCT01109004 National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI) Multiple Myeloma May 2010 Phase 3
NCT02500251 E. Steve Woodle|GlaxoSmithKline|University of Cincinnati Renal Transplant Rejection June 2015 Phase 1|Phase 2
NCT01114048 Chonnam National University Hospital Multiple Myeloma March 2010 Phase 2
NCT01055301 Southwest Oncology Group|National Cancer Institute (NCI) Multiple Myeloma|Plasma Cell Myeloma July 2011 Phase 2
NCT01146834 Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc. Multiple Myeloma March 2011 Phase 3
NCT02495922 University of Heidelberg Medical Center Multiple Myeloma June 2015 Phase 3
NCT00908583 University of Cincinnati|Millennium Pharmaceuticals, Inc. HLA Sensitization May 2009 Phase 4
NCT03188172 University of Leeds|Myeloma UK|Celgene|Janssen, LP Multiple Myeloma July 1, 2017 Phase 2
NCT03168100 University of Arkansas Multiple Myeloma July 2017 Phase 2
NCT02563340 First Affiliated Hospital, Sun Yat-Sen University|Second Affiliated Hospital of Guangzhou Medical University Kidney Transplantation November 2015 Phase 1|Phase 2
NCT00581776 University of Wisconsin, Madison Mantle Cell Lymphoma May 2005 Phase 2
NCT02343042 Karyopharm Therapeutics Inc Multiple Myeloma October 2015 Phase 1|Phase 2
NCT00504751 Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc. Non-Hodgkin's Lymphoma May 2007 Phase 2
NCT01556347 Providence Health & Services Heart Transplantation July 2012 Phase 2
NCT00087867 Scios, Inc. Multiple Myeloma June 2004 Phase 2
NCT00433537 National Cancer Institute (NCI) Contiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Stage I Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma May 2007 Phase 2
NCT01208818 Assistance Publique - Hôpitaux de Paris Chronic Renal Failure With Uremic Nephropathy June 2011 Phase 3
NCT02553460 St. Jude Children's Research Hospital|Gateway for Cancer Research|Texas Children's Hospital Acute Lymphoblastic Leukemia January 29, 2016 Phase 1|Phase 2
NCT01408797 Fuzhou General Hospital|Terasaki Foundation Renal Transplantation|Uremia March 2011 Phase 1|Phase 2
NCT00771875 University of Cincinnati Graft Rejection September 2008 Phase 2
NCT02208037 National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI) Acute Leukemia|Chronic Myelogenous Leukemia|Myelodysplasia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Hodgkin's Lymphoma August 2014 Phase 2
NCT02440464 National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program Multiple Myeloma August 2015 Phase 2
NCT02666209 Dana-Farber Cancer Institute|Bristol-Myers Squibb Multiple Myeloma in Relapse|Multiple Myeloma
NCT03117751 St. Jude Children's Research Hospital|Bristol-Myers Squibb|Incyte Corporation|Shire Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma March 29, 2017 Phase 2|Phase 3
NCT02559778 Giselle Sholler|Dell, Inc.|Beat NB Cancer Foundation|Because of Ezra|Spectrum Health Hospitals Neuroblastoma September 2015 Phase 1
NCT01849783 University of Iowa|National Cancer Institute (NCI) Extramedullary Plasmacytoma|Isolated Plasmacytoma of Bone|Light Chain Deposition Disease|Primary Systemic Amyloidosis|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma April 2013 Phase 2
NCT01350232 Sidney Kimmel Cancer Center at Thomas Jefferson University|National Heart, Lung, and Blood Institute (NHLBI)|Thomas Jefferson University Sickle Cell Anemia|Sickle Cell-hemoglobin C Disease|Sickle Cell-β0-thalassemia September 2009
NCT00092222 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Lymphoproliferative Disorder|HHV-8|Malignancy|HIV September 17, 2004 Phase 2
NCT02719613 Bristol-Myers Squibb|AbbVie Multiple Myeloma July 11, 2016 Phase 2
NCT02057380 Astellas Pharma Global Development, Inc.|Astellas Pharma Inc Advanced Solid Tumors April 2014 Phase 2
NCT01088048 Gilead Sciences Indolent Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma April 2010 Phase 1
NCT03004287 University of Arkansas|Janssen, LP Multiple Myeloma July 1, 2017 Phase 2
NCT02525172 National Taiwan University Hospital Pompe Disease August 2015 Phase 4
NCT02265510 Incyte Corporation Advanced Cancer August 2014 Phase 1|Phase 2
NCT00006184 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Multiple Myeloma August 2000 Phase 2
NCT00276744 Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI) Pancreatic Cancer October 2005 Phase 2
NCT00183937 University of Southern California|Millennium Pharmaceuticals, Inc. Prostate Cancer April 2005 Phase 2
NCT00025376 University of Chicago|National Cancer Institute (NCI) Kidney Cancer October 2001 Phase 2
NCT00437086 Mayo Clinic|National Cancer Institute (NCI) Chronic Myeloproliferative Disorders|Leukemia September 2005 Early Phase 1
NCT00199212 Jules Bordet Institute Carcinoma Breast Stage IV October 2003 Phase 1
NCT00237627 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific May 2001 Phase 1|Phase 2
NCT00083460 University of Arkansas Multiple Myeloma December 2001 Phase 1
NCT00361088 H. Lee Moffitt Cancer Center and Research Institute|Millennium Pharmaceuticals, Inc.|National Cancer Institute (NCI) Multiple Myeloma August 2005 Phase 1|Phase 2
NCT00054665 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) B-Cell Lymphoma February 2003 Phase 2
NCT00200382 Montefiore Medical Center|Millennium Pharmaceuticals, Inc. Non-Small Cell Lung Cancer May 2004 Phase 2
NCT00574236 University of Wisconsin, Madison|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc. Metastatic Breast Cancer February 2006 Phase 2
NCT00512798 Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) Brain and Central Nervous System Tumors|Melanoma|Solid Tumor June 2003 Phase 1|Phase 2
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.6025 mL 13.0127 mL 26.0254 mL
5 mM 0.5205 mL 2.6025 mL 5.2051 mL
10 mM 0.2603 mL 1.3013 mL 2.6025 mL
Cell Assay
[1]

Bortezomib is dissolved in DMSO and stored, and then diluted with appropriate media (DMSO 0.1%) before use[1].

The human PC-3 prostate tumor cells are treated with Bortezomib (0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM, 10 μM) for 24-48 h in complete medium. Cytotoxicity is measured using a MTT assay[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1][4]

Bortezomib is prepared in 98% saline (0.9%), 2% ethanol, and 0.1% ascorbic acid (Mice)[1].
Bortezomib is dissolved in 5% DMSO solution (Rat)[4].

Mice[1]
Male nude mice (18-20 g; n=51) are used. Bortezomib (0.3 or 1.0 mg/kg) is administered in vehicle i.v. using a dose volume of 100 μL per mouse or directly into the tumor in a 10 μL volume. Due to the comparatively high levels of Bortezomib in the prostate, after i.v. dosing of radiolabeled drug, it is decided to examine the effects of this novel compound in the prostate, PC-3, xenograft tumor model. Animals are treated when the tumors become palpable (>300 mm3). Male nude mice (18-20 g; n=51) are used. Bortezomib (0.3 or 1.0 mg/kg) is administered in vehicle i.v. using a dose volume of 100 μL per mouse or directly into the tumor in a 10 μL volume. Due to the comparatively high levels of Bortezomib in the prostate, after i.v. dosing of radiolabeled drug, it is decided to examine the effects of this novel compound in the prostate, PC-3, xenograft tumor model. Animals are treated when the tumors become palpable (>300 mm3).
Rat[4]
Male Sprague-Dawley rats weighing 200-250 g are used. Bortezomib (0.05, 0.1, or 0.2 mg/kg) or vehicle (5% DMSO solution) is administered intraperitoneally (i.p.) twice a week for 2 weeks (on days 1, 4, 8, and 11). The administration schedule and doses of Bortezomib are determined based on clinical treatment (1.3 mg/m2 of Bortezomib on days 1, 4, 8, and 11). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

384.24

Formula

C₁₉H₂₅BN₄O₄

CAS No.

179324-69-7

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.72%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Bortezomib
Cat. No.:
HY-10227
Quantity: